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Although conventional therapies for metastatic cancers have made significant progress in recent 
years, they are relatively nonspecific and have many deleterious side-effects.  Recently, novel 
therapies, including adoptive cellular immune therapies have had sporadic, but spectacular 
success in cancers such as malignant melanoma and renal cell carcinoma: tumors in which an 
immune response has been demonstrated.  However, other physiological mechanisms, such as 
blood coagulation inhibit the immune response against cancers. Our previous work has shown 
that one of these coagulation proteins, soluble fibrin (sFn), inhibits unstimulated and activated 
lymphocyte adherence to tumor cells by blocking leukocyte integrin (CD11a/CD18) binding to 
tumor cell CD54, suggesting that sFn is an immunosuppressive agent in cancer. Since these 
receptors are also involved in lymphocyte/endothelial cell adherence and diapedesis (a necessary 
step in the immune response to cancer), it was hypothesized that sFn inhibits these functions, and 
that blockade of this inhibition using specific peptides would restore these immune responses.  
Fluorescently labeled lymphocytes and Interleukin-2 activated lymphocytes (LAK cells) were 
incubated with sFn (or its components; fibrinogen, Gly-Pro-Arg-Pro, or thrombin) in the presence 
or absence of specific blocking peptides.  Lymphocyte and LAK cell adherence to endothelial cell 
monolayers was measured by perfusion at physiological shear rates in a microscope-mounted 
closed perfusion chamber, followed by image analysis using Image Pro Plus software. Diapedesis 
was measured by detection of fluorescence in 24-well microplates following immune cell 
incubation (18 h) with endothelial cell monolayers grown in transwells.  SFn inhibited 
lymphocyte (54.1 + 11.3 %) and LAK cell (43.9 + 4.4 %) adherence to sFn pretreated endothelial 
cells, and intermediate values were obtained from sFn pre-treatment of only one cell type. 
Adherence was restored by peptide mediated blockade of sFn/CD54 binding, but not by CD11b 










4.9 %) and restoration was observed using blocking peptides.  These results confirm the stated 
hypotheses, and if physiologically relevant, suggest that sFn is an etiological agent in tumor 
growth and metastasis, and that blockade using fibrin specific peptides may enhance the 
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CHAPTER 1: LITERATURE REVIEW AND INTRODUCTION 
1. 1  Introduction 
Conventional treatments for cancer primarily include “broad spectrum” approaches such as 
chemotherapy, radiotherapy and invasive surgery.  By contrast, the ability of the humoral, innate, 
and cellular immune responses to specifically target and treat cancer has attracted greater research 
and clinical interest in recent years.  To this end, the field of immunotherapy in cancer has 
developed a number of therapeutic strategies in the treatment of cancer, including antibody and 
cytokine based treatments, combined chemotherapy and immunotherapy, and adoptive 
immunotherapy.  Adoptive immunotherapy was pioneered by Stephen Rosenberg and others in 
the 1980’s, and with various modifications and improvements, has resulted in a small but 
tantalizingly significant response in some melanoma and renal cell carcinoma patients, as 
evidenced by a recent Science paper (Morgan, 2006). However, the mechanisms involved in 
leukocyte and activated or modified leukocyte homing and specific tumoricidal responses to 
cancers is still not fully understood, in part due to the multi-disciplinary interactions which are 
highly probable in such therapies.  These mechanisms necessarily involve leukocyte interactions 
with other molecular and cellular components of the blood, vascular endothelium, tissues and 
cancer cells. For example, our laboratory’s previous work has clearly shown that one of the end 
products of blood coagulation, soluble fibrin (which is present in elevated levels in many cancer 
patients; Iverson, 1995), significantly inhibits leukocyte adherence and killing of cancer cells in 
vitro, and enhances experimental metastasis (Biggerstaff, 2006; 2007, 1999).  Furthermore, the 
cell surface molecules which mediate this inhibition (leukocyte integrin CD11b/CD18 and its 
receptor CD54) are also highly important in leukocyte adherence and diapedesis across vascular 
endothelium.  In bringing the subjects of immunotherapy and blood coagulation into cancer 










leukocyte adherence and diapedesis.  It was further hypothesized that blockade of soluble fibrin 
binding to these receptors, using specific peptides (our lab has previously demonstrated peptide 
mediated restoration of leukocyte adherence to tumor cells; Biggerstaff, 2006), would restore the 
ability of leukocytes to adhere to and migrate across endothelial cell (EC) monolayers. 
Confirmation of this hypothesis would suggest that peptide therapies may be important as 
adjuvants to adoptive immunotherapies in the treatment of cancer. 
 
The following sections describe work in the areas of cancer biology, cancer immunology, and 
fibrin biology which have led to the generation of the primary hypotheses for this project. 
 
1. 2  Cancer 
1. 2. 1  Epidemiology of Cancer  
Cancer is the second leading cause of death in the United States, with more than one million 
Americans diagnosed with the disease each year, with this number likely to increase as the 
population increases.  A recent report released by the nation's leading cancer organization finds 
that although Americans' risk of dying from cancer continues to drop, maintaining a trend that 
began in the early 1990s, the rate of new cancer development remains stable (Howe, 2003). 
 
Localized cancer, or stage I of disease, is when tumor cells begin to exhibit invasion and 
disruption of local tissues to form a primary lesion. Tumor cells then invade the local lymphatic 
system and spread to the regional (stage II) or extended regional (stage III) draining lymph nodes 
as secondary tumors. Finally tumor cells invade into the blood stream where characteristic 
patterns of blood-borne metastasis indicate the onset of stage IV of disease. Particular tumors 










1. 2. 2  Malignant Melanoma 
Melanoma is the most serious form of skin cancer.  According to the Cancer Research Institute, 
although melanoma accounts for only about 5% of all skin cancers, it is responsible for more than 
75% of skin cancer-related deaths. Furthermore, melanoma cases in this country have more than 
doubled in the past 2 decades, with the rise expected to continue. The American Cancer Society 
projects that in 2007, the number of new cases of melanoma is estimated at 59,940, and the 
number of fatalities estimated at 8,110 (Jemal, 2007).  Furthermore, melanoma is projected to 
affect 1 in 50 Americans by the year 2010 (Howe, 2003). 
 
There are many risk factors that can lead to the onset of melanoma, including, but not limited to, 
exposure to chemicals or ultraviolet radiation (Austin, 1984; Holman, 1986), diet (Mackie, 1980), 
and genetic predisposition (Houlston, 1999).  Exposure to sunlight appears to be the most 
significant factor involved in the observed increase though; many dermatologists believe there 
may be a link between childhood sunburns and melanoma later in life (Weinstock, 1989). 
 
1. 2. 3  Clinical Presentation of Melanoma 
Malignant melanoma is a neoplastic disease characterized by uncontrolled proliferation of 
melanocytes, or the pigment of the skin.  There are various forms of cutaneous malignant 
melanoma, but the progression of disease in each form follows a similar pattern of growth and 
clinical deterioration (Roses, 1983).  The most benign types of melanoma are very slow growing 
and, apart from a visible skin lesion, are generally symptomless.  In many cases, it may take 
several years to become invasive.  Generally, the first sign of invasion by melanoma is an 
increase in cell proliferation, or an increase of horizontal dimension across the surface of the skin, 










vertical plane of the skin, or subcutaneous growth.  The final growth patterns observed in the 
progression of melanoma include the formation of local and distant metastases which often 
proceed rapidly following the vertical expansion of melanoma (Roses, 1983). 
 
1. 2. 4  Metastasis of Melanoma 
 
Melanoma, as all cancers, is characterized by abnormal division of cells, combined with 
malignant behavior of these cells. Metastasis is the unequivocal hallmark of the phenotypically 
malignant cell.  Malignant melanoma cells tend to spread, either by direct growth into adjacent 
tissue through invasion, or by implantation into distant sites by metastasis, whereby the cancer 
cells break away from the primary tumor and move through the bloodstream or lymphatic system 
to other locations, and grow.  Distant metastases can develop very rapidly, involving most 
internal organs.  The progression of a tumor from benign and localized to invasive and metastatic 
growth is the major cause of poor clinical outcome in cancer patients (Hofman-Wellenhof, 1996). 
 
1. 2. 5  Spontaneous Regression of Melanoma 
Melanoma is an unusual cancer in that it exhibits a relatively high level of spontaneous regression 
of the primary growth (approximately 7-8%; Smith, 1965; McGovern, 1972).  The only other 
malignant tumor that has demonstrated any degree of significant regression is renal cell 
carcinoma (de Riese, 1991). Unfortunately though, primary melanoma regression is not always 
considered a good prognostic sign, as metastases are often observed shortly thereafter (Kroon, 
2004). 
 
Histological observation of tissues present at the site of melanoma regression include a 










population all the way to a thick band of lymphocytes on the surface of the dermis (McGovern, 
1972). Observations indicate that these lymphocytes are capable of cytotoxicity to melanoma 
cells.  The lymphocyte infiltrate also disappears following regression, implying that the response 
is specifically mounted against the melanoma cells (McGovern, 1972). 
 
1. 2. 6  Conventional Treatment of Melanoma 
If melanoma is recognized and treated early, it is much more manageable and results in better 
prognosis. If it remains undetected, it will spread or metastasize to other parts of the body. The 
prognosis and treatment options for the treatment of melanoma depend on the many factors 
including the stage of disease, the location and size of the tumor, the presence of bleeding or 
ulceration at the primary site, and the patient's general health. Conventional treatment of 
melanoma falls into three broad categories.  The first method employed is surgery to remove 
the tumor, which is the primary treatment of all stages of melanoma and by far the most 
effective means of treatment provided it is detected early.  In the presence of secondary 
deposits and/or uncontrollable primary growth that make surgery impractical, another option 
for treatment is chemotherapy. Chemotherapy is when drugs are used to stop the growth of 
cancer cells, either by killing the cells or by stopping them from dividing. The third treatment 
option for melanoma is radiation therapy, which uses high-energy x-rays or other types of 
radiation to kill cancer cells or prevent them from growing (Kroon, 2004).  
 
These conventional treatments are often plagued by a number of side effects and problems.  
Most chemotherapy drugs are made to kill fast-growing cells, but because these drugs travel 
throughout the entire body, they can also affect normal, healthy cells.  Although radiation is 










tissues is the cause of many side effects including, but not limited to, nausea and vomiting, 
fatigue, soreness, rash, mental depression and anxiety, and hair loss.  Additionally, these 
treatments cause a decrease of a patient’s immune system, which can often lead to secondary 
ailments.  Similarly, surgery is often invasive and can lead to subsequent infection or other 
problems. 
 
Emerging novel therapies, such as the adoptive transfer of activated or engineered 
lymphocytes for the treatment of certain cancers, are designed to overcome this vast array of 
side effects.  These new treatments use the body’s own immune cells to specifically target or 
“home” to the site of the tumor.  Furthermore, these immune effector cells are removed from a 
patient prior to being manipulated and pretreated, followed by reintroduction back into the 
patient.  This potentially eliminates or lessens the risk of side effects due to harsh treatments in 
vivo. 
 
1. 3  Cellular Immunity and Cancer 
1. 3. 1  Background 
It has been over one hundred years since William Coley observed that tumor regression could 
be induced by stimulating the immune system with bacterial toxins (Coley, 1893).  He 
reported that direct inoculation of bacteria into the site of a tumor, often led to high fever and 
other symptoms associated with an intense immune response, but ultimately led to complete 
regression in a fraction of patients with various types of advanced cancer.  Coley’s work was 
later reviewed by his daughter, where she detailed 30 complete remissions, which were 
representative of the 270 complete remissions out of 1200 patients treated with toxins by her 










abandoned in favor of radiotherapy and chemotherapy, which together with surgery are still 
the major forms of cancer treatment today. In the mid 1970’s, it was theorized that tumor 
necrosis factor and interferon(s) may have been the primary factors in the exhibited immune 
response, however Coley’s results could not be reproduced to further study the exact 
mechanism. 
 
In spite of the mixed acceptance of this work, the concept of a role for the immune response in 
the control and elimination of malignant cells survived, giving rise to a new theory. In 1959, it 
was proposed that a specific, adaptive immune response may evolve so as to protect the body 
from neoplasia.  This theory was later termed the “immune surveillance” theory (Burnett, 
1970), which stated that when aberrant cells with proliferative potential arise in the body they 
will carry new antigenic determinant on their cell surfaces, which will trigger an immune 
response to destroy the aberrant cells similarly to when an allograft (foreign tissue implant) is 
destroyed.  According to this theory, cancer would only develop due to some failure of 
immune function, such as immunosuppression, or by adoption of immune evasion mechanisms 
by the tumor.  The extent to which this actually occurs in vivo remains a topic for debate, but 
there is now considerable evidence to support this theory including spontaneous remission, 
tumor infiltrating lymphocytes, and increased disease in immunosuppressed individuals 
(Blattman, 2004). Therefore, many strategies for cancer treatment focus on augmenting the 
immune system so as to increase its surveillance for, and subsequent destruction of cancer 
cells. 
 
More recently, some of the mechanisms that operate in the recognition and elimination of 










for T lymphocytes in conferring the specificity of tumor rejections. There is also evidence for 
natural killer cells (NK), macrophages, and eosinophil involvement in immune mediated anti-
tumor activity (Silverstein, 1999). 
 
In humans, direct evidence for a role of the immune response in immunity to tumors was 
lacking for many years.  The occurrence of spontaneous regressions of a number of tumors 
(especially malignant melanoma), the presence of mononuclear cellular infiltrates in many 
tumor types, and the response of certain tumors to immunotherapy all provided circumstantial 
evidence of the presence of an immune response to the tumor in a proportion of patients, and 
that immune intervention might provide a therapeutic strategy for human cancer. 
  
1. 3. 2  Lymphocyte Recirculation and Infiltration 
Lymphocytes are known to continuously circulate from blood to the lymphatic system via 
lymphoid and nonlymphoid tissues to fulfill the function of immune surveillance (Masuyama, 
1992).  In 1964, James Gowans demonstrated that lymphocytes spend between 2 and 12 hours 
in the blood before they appeared in the lymph or lymphoid organs (Gowans, 1964).  
However, in order for lymphocytes to recirculate through tissues, they must initially adhere to 
vascular endothelium and exit through the vessel walls in order to migrate through 
neighboring cells and extracellular matrix to a damaged tissue. The vascular endothelium is a 
single-cell layer that forms a continuous lining for the large container that holds circulating 
blood. The majority of this lining is found in the microcirculation of the capillary beds, where 
the surface area is very high, and the contact between the EC and blood components is 
maximized (Silverstein, 1999). Leukocyte emigration from the blood through the endothelial 










involves a coordinated function of a variety of adhesion receptors on the surface of leukocytes 
and EC (Carlos, 1994; Springer, 1994). 
 
Acute inflammatory response mobilizes leukocytes to sites of inflammation, and results in 
increased adherence of lymphocytes and other inflammatory cells to endothelium (Silverstein, 
1999).  Thus, the migration of lymphocytes across the vascular endothelial cell wall is a 
prerequisite in the implementation of lymphocyte function (Oppenheimer-Marks, 1990). The 
majority of lymphocytes are capable of tissue selective trafficking (termed “homing”), 
recognizing organ-specific adhesion molecules on specialized EC (Butcher, 1980).  A multi-
step model for leukocyte homing has been proposed and confirmed by various in vitro and in 
vivo models.  The first interactive step is the slow rolling of leukocytes along the endothelial 
lining, which subsequently may result in firm adhesion, diapedesis, and finally transmigration 
through endothelium into to surrounding tissue (Luscinska, 1996; Bevilacqua 1993; Springer, 
1994; Butcher, 1991). 
 
Clinical and pathologic evidence indicates that tumors can stimulate immune responses, such 
as the presence of these mononuclear cell infiltrates (Kroon, 2004). These immune cells 
respond to "danger" signals, which can be provided by growing tumors as a consequence of 
the genotoxic stress of cell transformation and disruption of the surrounding 
microenvironment.  Under ideal conditions, these signals will induce inflammation, activate 
innate effector cells with anti-tumor activity, and stimulate professional antigen-presenting 
cells to subsequently trigger an adaptive response by T and B lymphocytes (Blattman, 2004).  
The most potent of these cells is considered to be the natural killer, or NK cell (Hanna, 1980), 










polymorphonuclear neutrophils (Kindzelskii, 1999), show considerable anti-tumor cell activity 
after appropriate stimulation with cytokines or tumor cell products. 
 
Further evidence for infiltration is provided by the observation of lymphocyte proliferation 
(hyperplasia) in lymph nodes draining sites of tumor growth (Vetto, 1997).  In many tumors, 
there is evidence of cytokine effects, such as increased expression of class II major 
histocompatibility complex (MHC) molecules (Sikorska, 1999), and intercellular adhesion 
molecule-1 (ICAM-1; CD54) (Terol, 1998), suggesting an active immune response at the 
tumor site. The spontaneous regression of tumors such as melanoma (Halliday, 1995), and 
renal cell carcinoma (Jantzer, 1998), which are associated with dense peri- and intra-tumor 
lymphocytic infiltrates, is also suggestive of an immune mediated anti-tumor response. 
 
1. 3. 3  Leukocyte and Endothelium Interactions 
Inflammation is marked by the migration of leukocytes and plasma to a site.  This is 
accomplished through an increased vascular permeability caused by retraction of EC and by 
enhanced migration of leukocytes across the local vascular endothelium and in the direction of 
the site of inflammation (Ugarova, 1998). Recirculating lymphocytes, monocytes, and 
granulocytes bear receptors that bind to cell-adhesion molecules on the vascular endothelium, 
enabling these cells to extravasate into the tissue (Shimizu, 1991; Diamond, 1990; Steeber, 
1999). 
 
Some of these adhesion molecules are expressed constitutively, while others are only 
expressed in response to localized concentrations of cytokines produced during inflammatory 










1993; Barkalow, 2000; Carlos, 1994), integrins (Carlos, 1994; Adams, 1997; Beekhuizen, 
1993), and immunoglobulins (Carreno, 1995). Selectins are thought to be involved in the 
initial rolling of leukocytes along the endothelium, after which integrin binding occurs, 
followed by diapedesis into the underlying tissue. The β1 and β2 integrins are also important 
mediators of leukocyte (and dendritic cell) adherence to CD54 (ICAM-1) and VCAM on EC 
(Steeber, 1999). 
 
1. 3. 4  Leukocyte and Endothelial Cell Adhesion  
The mechanisms by which vascular EC capture circulating leukocytes are now well 
characterized and many of the ligands that contribute to their adhesion and subsequent 
transvascular migration identified (Osborn, 1992; Springer, 1994). Lymphocyte 
transendothelial migration has been reported to be dependent on lymphocyte activation via 
signaling through the T cell and the interleukin-2 (IL-2) receptor (Pryce, 1997). Furthermore, 
to facilitate the retention and migration of leukocytes to an inflammatory site, both cell types 
(leukocytes and EC) express outer surface cellular adhesion molecules (CAM's).  When these 
molecules are "activated", they undergo conformational changes increasing their affinity for 
binding to complementary ligands. 
 
Previous studies have also shown that initial capture of immune cells from the circulation 
occurs via endothelial selectin molecules that result in weak attachment and, under conditions 
of flow, result in leukocyte rolling along the vessel wall (Springer, 1994).  Leukocytes further 
bind to the adhesion receptors ICAM-1 and VCAM-1 on the endothelial surface before 
undergoing transendothelial migration (Luscinskas, 1995; Shimizu, 1991).  ICAM-1 is also 










basis of this function is poorly understood (Millan, 2006).  
To further facilitate the retention and migration of leukocytes to an inflammatory site, there 
are also a number of adhesion molecules present on the leukocytes that can mediate cell 
adhesion. Four members of the ß2 subfamily of integrins have been identified: αMß2 (Mac-1, 
CD11b/CD18, and CR3), α Lβ2 (leukocyte function–associated antigen and CD11a/ CD18), 
αXß2 (p150,95 and CD11c/CD18), and αDβ2 (CD11d/CD18) (Van der Vieren, 1995; Larson, 
1990). Two of the leukocyte β2 integrins, CD11a and CD11b, have been reported to bind to 
ICAM-1 (and ICAM-2) on the tumor cell (Diamond, 1990, Male, 1994; Steeben, 1999).  It has 
previously been shown that CD11a, a member of the integrin family, is present on 
lymphocytes and largely mediates adhesion between lymphocytes and EC. (Masuyama, 1992). 
Furthermore, a tight binding event and subsequent migration through the EC wall has further 
been shown to be mediated predominantly by the CD11a/ICAM-1 pairing (Oppenheimer, 
1990; Oppenheimer, 1991; Kavanaugh, 1991; Yednock, 1992). 
Many new strategies for the treatment of cancer focus on augmenting the immune system so as 
to increase its surveillance for, and subsequent destruction of cancer cells.  Furthermore, the 
therapies are often based on augmentation or activation of such receptor/ligand pairs that are 
present in leukocyte infiltration and subsequent attack of tumor cells. 
 
1. 3. 5  Immunotherapy of Cancer  
Immunotherapy refers to any approach aimed at mobilizing or manipulating a patient's 
immune system to treat or cure disease (Steinman, 2004).  It attempts to harness the power and 
specificity of the immune system for treatment of malignancy as previously described.  










and in some cases destroy even very large established tumors (Muranski, 2006). 
The various forms of immunotherapy may be classified into two main groups: active and 
passive.  Non-specific, active therapy involves activation of the immune system with agents 
such as PHA (adjuvant therapy).  Specific, active therapy includes vaccinating cancer patients 
with tumor derived extracts.  Unfortunately, clinical trials of tumor-specific active therapy (i.e. 
vaccination) have so far been disappointing, with objective response rates of 5% or less 
regardless of histology (Rosenberg, 2004). 
 
Specific passive immunotherapy involves treatment with monoclonal antibodies directed 
against tumor antigens.  Treatment with tumor antigens, or tumor infiltrating lymphocytes 
cultured with tumor antigens, are other forms of specific immunotherapy.  Passive 
immunotherapy may be non-specific, specific, or a combination of both.  Non-specific 
immunotherapy includes treatment with cytokines or LAK cells, which are discussed further 
below. 
 
1. 3. 5. 1  Interleukin-2 Activation of Lymphocytes  
A clear example of the effectiveness of immunotherapy to mediate cancer regression comes 
from studies of the administration of interleukin (IL)-2 to patients with metastatic melanoma 
and metastatic renal cancer (Rosenberg, 1998).  
 
Human IL-2 is a 15-kDa glycosylated interleukin, or hormone, that is only produced by 
activated T-cells and functions primarily in the generation of cell proliferation and induction 
of cytotoxic activity in activated T-cells, macrophages, and NK cells that is instrumental in the 










instead IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by 
lymphocytes, the cells that are responsible for immunity (Smith, 1980). 
 
There has been a total of 15% to 20% of patients with metastatic melanoma and metastatic 
kidney cancer experience objective regressions of metastatic disease, almost half of which are 
complete responses.  With 20-year follow-up in some patients, it was shown that treatment with 
IL-2 probably "cures" patients who experience a complete response, because 80% of these 
patients have ongoing complete responses (Rosenberg, 2005). Further, only 6 of 33 patients 
with either metastatic melanoma or kidney cancer who had complete cancer regressions have 
ever had disease recurrence (Rosenberg, 1998). The treatment can be safely administered with 
a treatment-related mortality of <0.5% (Kammula, 1998). Thus, it seems that patients with 
metastatic melanoma and metastatic renal cancer join that very small group of patients with 
solid tumors that can be cured by systemic treatment. Similar results from many series led the 
Food and Drug Administration to approve the use of high-dose IL-2 for patients with 
metastatic kidney cancer in 1992 and for patients with metastatic melanoma in 1998. The 
durability of complete responses was a decisive factor in the approval of these treatment 
regimens, which should be offered to all eligible patients with these metastatic cancers 
(Rosenberg, 2005).  
 
After the first descriptions of the effectiveness of IL-2 (Rosenberg, 1985; Lotze, 1986), 
immunotherapy has come of age, and substantial improvements based on increased scientific 












1. 3. 5. 2  Adoptive Immunotherapy 
In clinical trials associated with the administration of IL-2, one major side effect was toxicity 
using sufficient IL-2 concentrations to optimally activate the tumoricidal effect, presumably as 
a result of leukocyte activation. To overcome this effect, the peripheral blood lymphocyte 
population can be isolated from the patients using leukopheresis (or removal of leukocytes of 
blood followed by subsequent replacement of depleted plasma and red cells to donor).  These 
cells are then activated in vitro with high doses of IL-2 to induce lymphokine activated killer 
cells (LAK), which exhibit non-antigen dependent, non-MHC restricted cytotoxicity. LAK 
cells were first described by Yron in 1980, and were originally thought to be a new class of 
lymphocyte derived cytotoxic cell (Grim, 1982; Guinan, 1989). Since LAK behavior can be 
derived from a variety of lymphoid cells, the term LAK is a description of a cellular activity, 
rather than a specific cell type (Maghazachi, 1988). Following cellular activation, the cells 
were washed and reintroduced into the patient’s circulation, where they were expected to 
home to the tumors and kill them. This process is known as adoptive immunotherapy. 
This adoptive transfer of autologous lymphocytes with antitumor activity, expanded in vitro 
and reinfused into patients, can mediate tumor regression (Rosenberg, 1988), and recent 
advances in this field have dramatically improved the effectiveness of this approach (Dudley, 
2002, Dudley, 2003).  In 2002, Rosenberg et al. reported some of their most promising results 
to date.  The procedure involved removal of peripheral blood lymphocytes from melanoma 
patients, followed by reintroduction of LAK cells into the same patients.  The results of their 
studies were that the infused cells usually took up longterm residence, and in 10 of the13 
patients, their melanoma cells, including all metastases, regressed either partially or 
completely (Rosenberg, 2005).  Lymphodepletion before the administration of autologous 










melanoma, including those refractory to high-dose IL-2 and combination chemotherapy 
(Dudley, 2005). These studies demonstrate the effectiveness of immune T cells when 
administered to hosts actively depleted of T-regulatory cells, as well as cells that compete for 
homeostatic cytokines. 
 
Unfortunately, multiple factors, including tumor immune evasion, homeostasis and induction 
of tolerance, as well as suboptimal quality of transferred T cells, have hampered the otherwise 
promising attempts at driving tumor rejection (Ross, 1993; Yee, 2000; Dudley, 2001).  
 
To overcome some of the homing and other problems associated with LAK based 
immunotherapy, researchers have found immune cells deep inside some tumors, which have 
an enhanced “homing ability”, and have named these cells tumor-infiltrating lymphocytes 
(TILs). Success with TILs in lab animals led researchers to devise a strategy to increase the 
anti-tumor activity of TILs.  In the late 1980’s, clinical trials were begun by Rosenberg and 
other groups (Rosenberg, 1985; Kawakami, 1988; Heo, 1987), in which tumor infiltrating 
lymphocytes (TIL) were removed from excised tumors, stimulated with IL-2, and reinjected 
into cancer patients to promote tumor regression. 
 
Furthermore in a 2006 report, the Rosenberg group reported a 50% response rate according to 
RECIST criteria was reported in patients with metastatic melanoma treated with in vitro 
expanded TIL’s and IL-2 following a lymphodepleting nonmyeloablative preparative regimen 
of cyclophosphamide and fludarabine (Gattinoni, 2006; Hughes, 2005; Morgan, 2006). Using 
this method, 2 out of 6 patients had a regression period of over 2 years following treatment 










host’s immune system needs to be properly conditioned, in order to create an appropriate 
‘lymphoid space’ that is devoid of regulatory mechanisms. However, immunodepletion and 
adoptive therapy have not yet been tested in randomized studies, but the results of recent 
clinical trials using these methods are notable for their unprecedented response rates and the 
fact that the patients studied had previously failed other modes of immunotherapy including 
high-dose IL-2 and ACT (Dudley, 2002; Morgan, 2006). 
 
Although encouraging, the sporadic results obtained with adoptive immunotherapies may be 
explained if activated leukocytes interact in a more complex way with other molecules and cells 
in the circulation. These interactions have not been extensively studied, but there is mounting 
evidence that molecules of the blood coagulation system may play a major role in the modulation 
of the immune response. The following section brings together the interactions of the end 
products of the clotting system (fibrinogen and fibrin) with immune cells and EC with relevance 
to inflammation and cancer. 
 
1. 4  The Role of Fibrin(ogen) in Immunity and Cancer  
1. 4. 1  Background 
A relationship between cancer and abnormalities of the coagulation system has been recognized 
for over 100 years (Trousseau, 1865).  Thromboembolic disease (usually of unknown etiology), 
refractory to anticoagulant therapy, may be an early detectable sign of an underlying cancer, 
which could precede the onset of observable cancer by months or years. Although many cancer 
patients exhibit clinically significant hemostatic abnormalities, about 50% of all patients (> 90% 
with metastases) also have abnormal laboratory coagulation parameters (Trousseau, 1865).  Such 










and its precursor fibrinogen (Fg), which may also be an early marker of undiagnosed malignancy 
(Andrassy, 1980).  
 
A role for coagulation in tumor biology is further inferred by the anti-tumor effects of 
anticoagulant drugs, such as heparin or warfarin (Zacharski, 2005; Biggerstaff, 1997) and in a 
number of both experimental and spontaneous animal tumor models (Hilgard, 1976; McCulloch, 
1987; Eichbaum, 1975; Biggerstaff, 1997). However, these therapies also increase the risk of 
bleeding due to inhibition of normal clotting. 
 
1. 4. 2  Fibrin(ogen) and Soluble Fibrin in Disease 
During the past two decades there has been an increasing appreciation of the multifaceted role 
fibrin(ogen) plays in the immune and inflammatory reactions. Although presumed for many 
years, many of the roles attributed to fibrin(ogen) have only recently been substantiated.  In this 
regard, much of the available evidence indicates that fibrin(ogen) operates as an antagonist, or 
that the adhesive potential is realized in a host of diseases and contributes to the progression of 
those diseases. We, and others, have speculated that tumor growth and propagation by 
fibrin(ogen) may be an inadvertent consequence of the protein's role in inflammation. 
Furthermore, some researchers are willing to attribute some or most of the pathogenesis of cancer 
to adhesive inflammatory events involving fibrin(ogen) (Palumbo, 2002; Simpson-Haidaris, 
2001; Retzinger, 1999).  Presuming their ideas are correct, interfering with those events should 
mitigate disease.   
 
Following its secretion from the liver, the protein exists in plasma, the lymph, and interstitial fluid 










inflammatory challenges resulting in increased hepatic expression, the induction of extrahepatic 
expression, and increased circulating protein (Molmenti, 1993; Lee, 1996; Guadiz, 1997). In 
healthy individuals, the concentration of fibrinogen in plasma is reported to be between 4 and 10 
µM (Retzinger, 1999).  However, this concentration can increase by as much as 200 to 400% 
during times of physiological stress, such as disease (Shultz, 1990). 
 
Fibrin(ogen) deposition is a universal feature within injured tissues and inflammatory foci.  In the 
late 1950's, fibrin(ogen) was shown to be a component of tumor-induced inflammation, and more 
recently fibrin(ogen) (and derived materials like fibrin) have been shown to accumulate within 
tumor stroma and envelop tumor cells (Retzinger, 1999).  Furthermore, in vitro studies (Smiley, 
2001; Sitrin, 1998; Rubel, 2002; Rubel, 2001; Shi, 2001) have shown that fibrin(ogen) can 
profoundly alter leukocyte function, leading to changes in cell migration, phagocytosis, NF-kappa 
B–mediated transcription, production of chemokines and cytokines, degranulation, and other 
processes. Furthermore, recent reports from in vivo studies suggest that pulmonary metastasis is 
reduced in fibrinogen deficient animals (Palumbo, 2002).  
 
The presence of sFn in blood has, until recently, been considered a benign marker for the 
presence of an ongoing coagulopathy.  However, others have reported a direct role for sFn in 
melanoma metastasis in an experimental animal model (Rickles, 1992; Biggerstaff, 1999). 
Several other studies suggest that sFn may be a prognostic marker in cancer (Beer, 2002; Spero, 
1980), but no clinical studies have been performed to date to directly associate sFn with increased 
metastasis. 
 










been reported to result in inhibition of the immune response to cancer.  Gunji et al. showed that 
fibrin deposition on tumor cells during migration in the blood could protect them from 
elimination by NK cells or other cytotoxic cells (Gunji, 1988).  Furthermore, this was also found 
particularly when using immunotherapies involving lymphokine (Interleukin-2) activated killer 
(LAK) cells (Gunji, 1999), mitogen (PHA) stimulated T cell blasts, or re-injected 
tumorinfiltrating leukocytes (TIL).  Furthermore, immunosuppression induced by fibrin 
degradation products has also been reported (Girmann, 1976; Donnel 1989).  Furthermore, our 
laboratory also recently demonstrated that sFn also inhibited lymphocyte and IL-2 activated LAK 
cell adherence and cytotoxicity against tumor cells (Figures A-1, A-2; Biggerstaff, 2007).  All of 
these results collectively suggest that sFn may be an immunosuppressive agent in cancer, and that 
it is involved in the etiology of metastasis.  Furthermore, successful transfer and treatment by 
these means are more commonly observed in those patients with less severe, early stage disease.  
This coincides with the findings that sFn is more elevated in those patients with severe prognosis.  
These pieces of information taken collectively, support the hypothesis that sFn is an 
immunosuppressive agent that inhibits lymphocyte recognition, binding, and diapedesis of 
endothelium, which allows for greater success of metastasis. 
 
1. 4. 3  Fibrinogen Structure and Degradation  
Fibrinogen is a dimeric protein, each half of which is composed of disulfide-bonded polypeptide 
chains designated Aα, Bβ, and γ.  The designations "A" and "B" refer to fibrinopeptides A (FpA) 
and B (FpB) that constitute the amino terminal residues of the A and B chains (Retzinger, 1999).  
 
The conversion of fibrinogen to fibrin manifests as a multi-step transformation of the original 










are catalyzed by thrombin, a trypsin-like serine protease, which hydrolyzes specific Arg-Gly 
bonds within the α and β chains of fibrinogen (Retzinger, 1999). Figure 1.1 is a diagram of 
fibrinogen structure and its sites of thrombin cleavage. 
 
Fibrinogen is thought to be rather inert in circulation but it becomes reactive toward itself and a 
number of proteins and cell types upon conversion to fibrin (Medved, 2001).  Conversion of 
fibrinogen to fibrin results in the exposure of multiple binding sites that provide its interaction 
with various other proteins and cells (Medved, 2001). Furthermore, fibrin(ogen) has been shown 
to suppress lymphocyte functions (Plow, 1986). 
 
As earlier discussed, there are an abundance of cells present near those sites of inflammation, or 
cancer growth that have receptors for fibrin(ogen).  Fibrin(ogen) binds to a wide range of cellular 
receptors, including two of the leukocyte β2 integrins, αMβ2 (Mac-1) and αXβ2 (p150,95) 
(Wright, 1998; Altieri, 1995; Altieri, 1988), and the β2 integrin receptor, CD54 (ICAM-1) 
(Languino, 1995; Gardiner, 1997), which are important mediators of leukocyte diapedesis. Many 
of the effects of fibrin(ogen) on leukocyte activity appear to be mediated by a specific receptor on 















1. 4. 4  Anticoagulation Therapy of Cancer 
Fibrin deposition around solid tumors may protect the host from tumor cell invasion by blocking 
their entrance into the circulation (Colucci, 1981).  Furthermore, early studies using isotope 
labeled tumor cells showed that tumor cell deposition occurred regardless of whether animals 
were anticoagulated, but that subsequent metastatic growth was decreased by anticoagulant 
therapy, implying a role for fibrin in metastatic tumor growth (Fisher, 1967).  Recently, 
Costantini and Zacharski reviewed the evidence addressing the significance of blood coagulation 
activation in fibrin deposition in tumor cells (Costantini, 1993). As for the involvement of 
fibrin(ogen) in malignancy, it has been proposed that the protein envelops tumor cells thereby 
protecting them from immune surveillance (Dvorak, 1981), and provides an intravascular matrix 
for trapping and anchoring malignant cells following their release from a parent tumor.(Markus, 
1984). A role for coagulation in tumor biology is further inferred by the anti-tumor effects of 
anticoagulant drugs, such as warfarin and heparin (Zacharski, 2005), and other coumadin 
derivatives (Gasic, 1983), thrombin inhibitors (Hu, 2004; Asanuma, 2004), and in a number of 
both experimental and spontaneous animal tumor models (Hilgard, 1976; McCulloch, 1987; 
Eichbaum, 1975; Amirkhosravi, 1995). 
 
Anticoagulant therapy, in combination with chemotherapy, has been applied with some success in 
the past.  However, anticoagulation can be seen as a drawback in many patients, particularly those 
undergoing surgery, because excessive blood loss can result.  Recently, alternative approaches 













1. 5  Peptide Therapy  
1. 5. 1  Background 
There are multiple examples in nature, where peptides are used as ligands to influence the 
function of specifically binding target proteins (Buerger, 2003).  Furthermore, there is a wide 
spectrum of tools now used to interfere with the function of a given gene product, including 
selected inhibitory peptides (Borghouts, 2005).  Most peptides being considered for therapeutic 
purposes at this time exert their action on the cell surface. Peptides bind to cell surface proteins 
and act by inducing or inhibiting one or more signal transduction pathways.  Furthermore, small 
peptides are able to recognize specific protein domains and thus interfere with enzymatic 
functions or protein-protein interactions (Buerger, 2003).  Proteins and peptides are 
experimentally selected for high-affinity cellular interactions with pre-determined target 
structures that are emerging as important molecules.  These advances could serve to extend the 
conventional administration of drugs.  In a few model systems, peptides have already been used 
to manipulate crucial regulatory networks in cancer cells (Buerger, 2003; Kardinal, 2001; Mai, 
2001; Wang, 2000; Zhang, 2001).  They can target specific intracellular proteins required by 
cancer cells for proliferation and invasion.  It is conceivable that individual peptides can also be 
derived to inhibit function in a targeted fashion.  These peptides can be used for mono therapy or 
in combination with conventional chemotherapeutic agents in order to better treat cancer 
(Borghouts, 2005). 
 
1. 5. 2  Natural vs. Synthetic Peptides 
Inhibitory peptides can either be designed from both naturally occurring binders or synthetically 
manufactured.  Usually crystallographic data are required for the first approach, to study the 










findings (reviewed in Borghouts, 2005) indicate that peptides with high affinity already exist for 
various targets, which can be used for therapeutic approaches without screening large peptide 
libraries.   
 
Furthermore, the use of small endogenous domains not only provides for high affinity, but also 
circumvents problems encountered with larger exogenous proteins, such as lower stability and 
higher immunogenicity if used in vivo (Borghouts, 2005). Unfortunately, the clinical fruits of 
many new therapeutic methods have not been abundant, in part because in vitro models used for 
screening often do not duplicate well in vivo.  This too has been true of the past decade of 
peptide-drug design for the treatment of cancer.  There are clear indications that smaller ligands 
are generally better for therapeutic use (Reilly, 1995).  Compared with antibodies and their 
fragments, peptides are considerably smaller, and generally should not elicit an immune response 
upon repeated administration (Aina, 2002; Nilsson, 2000). Therefore, peptide ligands may 
overcome several limitations of antibody therapy and diagnosis (Mori, 2004).  
 
Furthermore, what is needed is the therapeutic equivalent of what Muller et al. refer to as “smart 
bombs”, or the ability to selectively inhibit inflammation where it is damaging without interfering 
with beneficial functions of the inflammatory response (Muller, 2002).  Many current strategies 
lack this ability, and cause an added difficulty when dealing with any disease, particularly those 
associated with surgery.  
 
1. 5. 3  Specific Peptide Therapeutics 
As previously discussed, fibrin(ogen) is a ligand for many biological molecules. It has been 










neutrophils, and lymphocytes), EC, and tumor cells. Many different studies have been performed 
to further identify the specific amino acid sequences on these molecules responsible for 
interactions.  Furthermore, small peptides have been derived from fibrinogen, CD11b/CD18, and 
CD54, and tested for their ability to inhibit fibrinogen binding (Altieri, 1995; Ugarova, 1998; 
Yakubenko, 2001; D’Souza, 1996). Several other similarly derived peptides have been identified 
during the past several years, but these four specific sequences (and peptides) have been studied 
in detail by our lab (Biggerstaff, 2006).  In recent studies, it was shown that the following four 
peptides sequences significantly restored monocyte adherence (and cytotoxicity) to tumor cells, 
following pretreatment with (and inhibition caused by) sFn (Biggerstaff, 2006). Furthermore, 
Table 1-1 details the sequences, molecules of origin, and ligands associated with each peptide. 
 
1. 5. 3. 1  Peptide P1 Background  
Peptide 1, (P1; 117NQKIVNLKEKVAQLEA133 ) present on the fibrinogen γ-chain, reportedly 
binds to the CD54 sequence present on the 1st immunoglobulin domain (Altieri, 1995). As 
previously discussed, ICAM-1 is expressed by many cell types including EC, leukocytes and 
many cancers.  Furthermore, pretreatment of tumor cells with P1 was shown to block sFn from 
binding to tumor cells in our recent work (Figure A-3; Biggerstaff, 2006). 
 
Table 1-1. Specific Peptide Sequences, Molecules of Origin, and Ligands (Biggerstaff, 2006). 
 
Peptide # Sequence Molecule of Origin Ligand 
P1 NNQKIVNLKEKVAQLEA sFn (g-chain) CD54 (1st Ig) 
P2 YKSMKKTTMKIIPFNRLTIF sFn (g-chain) αMβ2 (αM I) 
P3 KVILPRGGSVLVTC CD54 (1stIg) sFn (g-chain) 











1. 5. 3. 2  Peptide P2 Background 
 Several peptides corresponding to potential fibrin(ogen)/CD11b binding domains have been 
identified over the past several years. Recently, Ugarova et al. revealed another possible binding 
site in the region of 377–395 of the fibrinogen chain that may be important (Ugarova, 1998). 
Furthermore, the P2 peptide (377YKMKKTTMKIIPFNRLTIG395), originally designated P2C, was 
shown to significantly  inhibit CD11b-mediated cell adhesion to immobilized fibrinogen and 
directly supported saturable binding to the M I-domain (Ugarova, 1998).  It is currently considered 
to be the major fibrin(ogen) γ-chain binding site for CD11b (αMβ2) and CD11c (αXβ2) (Ugarova, 
1998).  Furthermore, pretreatment of monocytes with P2 has recently been shown to block sFn 
from subsequently binding to cells, allowing restoration of binding to tumor cells (Figure A-3; 
Biggerstaff, 2006). 
 
1. 5. 3. 3  Peptide P3 Background  
The major fibrin(ogen) binding site on CD54 is in the 1st Immunoglobulin domain 
(8KVILPRGGSVLVTC21, designated P3 herein) (D’Souza, 1996), and binds to the fibrinogen γ-
chain.  Pretreatment of sFn with P3, prior to exposure to monocytes, has also been recently shown 
to restore monocyte binding to tumor cells (Figure A-4; Biggerstaff, 2006).  Specifically, P3 
binds the site taken to synthesize P1 herein (117NQKIVNLKEKVAQLEA133 ). 
 
1. 5. 3. 4  Peptide P4 Background 
The major fibrin(ogen) γ-chain binding site reported on CD11b (αMβ2) is in the αM I-domain 
(245KFGDPLGYEDVIPEADR261) (Yakubenko, 2001). Peptide 4 (P4) was created from this 
sequence, in order to block leukocyte binding to fibrin(ogen).  Furthermore, pretreatment of sFn 










binding to tumor cells (Figure A-4; Biggerstaff, 2006).  Figure 1.2 is a schematic diagram 
showing the sequences and specificities of each of these peptides on the sFn γ-chain and on 
CD11b (αMβ2) and CD54.  
 
As previously discussed, earlier studies (Biggerstaff, 2006), have shown that the addition of 
any/all of these peptides results in a significant restoration of adherence of sFn pretreated 
monocytes and tumor cells to one another (by a mechanism of CD11b and CD54; Figure A-5).  
However, since this project employs only lymphocytes and EC, the peptides designated P1 and 
P3 are being tested for their anticipated relevance to this model.  Whereas, P2 and P4, which are 
specific to the monocyte receptor and complementary sequence on sFn, were not expected to 
exhibit the same therapeutic potential for these particular cell types (due to the different 
expression of receptors). 
 
Additionally, previously performed experiments determined that the specific fibrin(ogen) 
adherence inhibitors did not affect fibrinogen clotting in the presence of thrombin in vitro.  
Furthermore, the peptides did not inhibit the normal coagulation cascade, as shown in re-calcified 
normal human plasma (Biggerstaff, 2006).  
 
1. 6.  Research Objectives and Hypotheses 
There are seemingly many factors that are physiologically relevant to the epidemiology of disease 
and prognosis in melanoma patients.  Furthermore, the relationship between host immune cells 
(leukocytes), the vascular system (endothelium), tumor cells, the cytokine network, and potential 
therapies is highly complex, as discussed.  Therefore, the primary goal of this project was to 


























Figure 1-2.  Model of Relevant Cellular and Fibrin(ogen) Receptor Sequences.  
Schematic diagram showing the amino acid sequences, sites of origin and effector 
molecules for four peptides (designated P1 – P4) reported to inhibit fibrin(ogen) binding 











synergistic interactions and inhibitory factors involved in tumor cell progression and metastasis.   
 
As presented above, fibrin(ogen) and sFn levels are often upregulated in cancer patients, and have 
been shown to act as immunosuppressors in many experimental animal models.  Furthermore, our  
lab has recently shown that sFn inhibits monocyte adherence to and cytotoxicity of tumor cells.  
More recently, we have found that sFn also inhibits lymphocyte and LAK cell adherence to tumor 
cells. 
 
There is also an abundance of evidence that these interactions are highly dependent on the 
CD11b/CD18, CD11b/CD18, and CD54 receptor interactions.  More specifically, sequences 
within these receptors have been identified that actively mediate binding to fibrin(ogen).  
Furthermore, researchers have discovered complementary sequences that have been recently 
identified on the fibrin(ogen) molecule that bind specifically to these sequences.  As a result, we 
have utilized these specific peptide sequences that have been shown to significantly restore levels 
of monocyte binding and cytotoxicity to tumor cells, even in the presence of sFn.   
 
Based on these results, it was hypothesized that sFn may also inhibit lymphocyte and LAK cell 
adherence to and diapedesis through EC.  We further hypothesized that a double blockade of sFn 
binding to CD54 on EC, using the above peptides (P1 and P3), would result in restoration of these 
effector functions without affecting normal clotting.  Further pretreatment with P2 and P4, those 
peptides specific for monocyte interactions, are expected to minimally affect binding and 
migration, due to the incongruence of receptor and ligand in this model.  
 










use immunochemistry and fluorescently labeled sFn to establish sFn binding to effector cells, 2) 
to determine the role of sFn in lymphocyte adherence to EC under flow conditions, 3) to 
determine the role of sFn in lymphocyte transmigration, or diapedesis through endothelium 
toward tumor cells in a standard microplate assay, and 4) to determine the effect of specific 
blocking peptides on sFn-induced inhibition of lymphocyte binding and diapedesis. 
 
Inhibition of lymphocyte function by sFn would have important implications in adoptive 
immunotherapy of cancer in which activated, or modified lymphocytes are reintroduced into the 











CHAPTER 2.  EXPERIMENTAL DESIGN, MATERIALS, AND METHODS 
2. 1  Experimental Design and Background 
2. 1. 1   HMEC-1 Endothelial Cells 
Human dermal microvascular endothelial cells (HMEC-1) were immortalized by transformation 
with SV40 virus (Ades, 1992).  This particular cell line was chosen for its previously documented 
characteristic endothelial cell receptor biology, in order to further explore the complex 
relationship between lymphocytes, tumor cells, and endothelium.  
 
HMEC-1 exhibits typical cobblestone morphology when grown in monolayer culture (Figure 
2.1).  It has previously been shown to bind to peripheral blood leukocytes and extra cellular 
matrix proteins via many specific cell adhesion molecules.  HMEC-1 can either constitutively 
express or can be induced to express key integrins including alpha-1,-2,-3,-4,-5,-6, and –V, as 
well as beta-1,-3,-4 and -5.  Furthermore, they have been shown to express immunoglobulin gene 
super family molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1), and a member of the selectin family, E-selectin (Xu, 1994). 
 
2. 1. 2  A375 Melanoma Cells 
The A375 human amelanotic malignant melanoma cell line was established from a solid tumor 
that was excised from a 54 year-old female with melanoma as described in Giard, et al. (Giard, 
1973).  This cell line was chosen due to its relevance to immunotherapy (melanoma) and due to 
its employment in our previous publications involving similar mechanisms.  Furthermore, A375 























2. 1. 3.   Immunostaining and Fluorescently Labeled Soluble Fibrin Assays 
2. 1. 3. 1 von Willebrand’s Factor 
Endothelial cell ultrastructure was initially described by Weibel et al. in the 1960’s. The cells 
contain numerous unique, electron-dense, membrane-bound organelles, called Weibel-Palade 
bodies (Weibel, 1964).  These particular structures contain a high concentration of von 
Willebrand factor (vWF), a large glycoprotein present in plasma.  When EC are exposed to 
certain agonists, such as thrombin or histamine, these Weibel-Palade organelles “flow” to the 
surface of the cell and their contents are secreted into the blood, causing fusion between their 
membranes and the cellular surface. Therefore, HMEC-1 cells were stimulated with thrombin 
(which is necessary to convert Fg to sFn) and immunostained for vWF. 
 
2. 1. 3. 2  CD54 (ICAM-1) 
The CD54 antigen is a 90 kDa transmembrane glycoprotein, which is related to the 
Immunoglobulin family.  As previously discussed, the CD54 antigen has been reported to 
mediate the adhesion of lymphocytes, monocytes, and neutrophils to both normal and activated 
endothelium. Therefore, HMEC-1 cells were stimulated with thrombin and stained for this 
antigen using indirect immunostaining to confirm presence of this receptor on this cell line.   
 
2. 1. 3. 3  CD25  
CD25, or Anti-IL-2R, recognizes an antigen that is the human low-affinity interleukin-2 receptor 
(IL-2R). Furthermore, CD25 expression is reported to be upregulated on activated lymphocytes, 
or LAK cells, compared to their lymphocyte precursors (Schlossman, 1995).  Therefore, 
monoclonal antibodies directed against this receptor were applied to differentiate these different 










2. 1. 3. 4  Oregon Green Labeled Soluble Fibrin on Effector Cells 
In previous studies, we have shown that Oregon Green labeled soluble fibrin binds to monocytes, 
lymphocytes, and A375 tumor cells (Figures A-6, A-7; Biggerstaff 2006, 2007).  In this project, 
we have employed the same method to show that sFn also binds to LAK and HMEC-1 cells.  
 
2. 1. 4  Leukocyte Adherence to Endothelial Cells Under Flow Conditions 
As earlier reported, postcapillary venules are major sites of leukocyte emigration in inflammation 
(Lawrence, 1990).  Furthermore, physiological shear rates in these regions are generally reported 
to be between 35-560 s-1 (Lawrence, 1990; Heisig, 1968). In general, the movement of leukocytes 
to the vessell wall and subsequent efficiency of attachment both depend on the blood flow, 
therefore utilization of a perfusion model is more physiologically relevant than other static, cell 
binding methods that are often employed (Abbitt, 2003). Furthermore, our work previously 
included performing optimization assays for our particular flow model, in order to employ a shear 
rate that falls within this reported range while still observing a significant number of binding 
events (Figure A-8; Biggerstaff 2006).  
 
To simulate the fluid shear stresses present in vivo, coverslips containing confluent endothelial 
cell monolayers were loaded into the FCS2 stage incubator (Bioptechs Inc., Butler, PA), on the 
stage of an inverted microscope to observe lymphocyte rolling and binding events.  The FCS2 
incubator is a closed, near-laminar flow, temperature-controlled perfusion chamber. Figure 2-2 































Figure 2-2. Bioptechs FCS2 System. A) Eight piece apparatus (1. Temperature 
sensors, 2. Heater contacts, 3. Perfusion connections, 4. Upper gasket, 5. 
microaqueduct slide (optical surface, perfusion guide and termperature control), 6. 
Lower gasket (defines flow geometry), 7. 40mm coverslip, 8. Self-locking base 















2. 1. 5  Lymphocyte Transmigration Through Endothelial Cells in Microplate Assays 
A static, transwell migration system (adapted from Sancho, 1999) was used to perform 
experiments to determine the ability of lymphocyte and LAK cell preparations to cross 
endothelium in the presence or absence of an underlying tumor layer. Furthermore, the role of 
various levels of sFn in inhibiting lymphocyte/LAK cell diapedesis was also explored.  Lastly, 
specific peptides were also added to the model, in addition to sFn, in order to test their abilities to 
restore the protein from inhibiting diapedesis. 
 
2. 2  Sterile Cell Culture Methods 
All cell culture was carried out under sterile conditions, and performed in a Class 2 biological 
safety cabinet following the University of Tennessee BSL-2 laboratory guidelines. 
 
2. 2. 1  Endothelial Cell Culture 
HMEC-1 (kindly provided by Dr. Tim Sparer) were cultured in high-glucose DMEM (Invitrogen, 
Carlsburg, CA) supplemented with 10% Fetal Bovine Serum (FBS; Atlanta Biologicals, Atlanta, 
GA), 2 mM L-glutamine (Hyclone, Logan, UT), and 100 µg/ml streptomycin/penicillin 
antibiotics (Hyclone).  They were grown in both 25 cm2 and 75 cm2 sterile tissue culture flasks 
(Costar, Cambridge, MA) at 5% CO2, at 37ºC in constant culture. 
 
2. 2. 2  Tumor Cell Culture 
A375 was purchased from ATCC (Rockville Pike, MD), and maintained in continuous cell 
culture in RPMI 1640 supplemented with Glutamax (Invitrogen) with 10% FBS, and 100 µg/ml 
streptomycin/penicillin antibiotics.  They were grown in both 25cm2 and 75cm2 sterile tissue 










2. 2. 3  Removal of Cells from Culture 
Cells were detached from the plastic flasks using approximately 3-6 ml (depending on flask size) 
of trypsin/EDTA (0.25%; Hyclone).  After trypsin was added, the flask was immediately placed 
into a 37ºC incubator, with 5% CO2 for approximately 4-6 min, or until cells dislodged easily 
from the plastic.  The cell suspension was transferred from the flask into a 15 ml centrifuge tube 
and topped off with RPMI 1640 with 10% FBS.  Cells were then centrifuged at 200 x g for 10 
min, to obtain cell pellets. 
 
2. 3  Isolation of Peripheral Blood Lymphocytes 
Venepuncture and disposal for this study was performed in accordance with the University of 
Tennessee Institutional Review Board approval (IRB# 6788B). 
 
2. 3. 1  Venepuncture 
Approximately 50 milliliters of peripheral blood were drawn from normal, healthy volunteers into 
6 ml 3.2% lithium heparin vacutainers (Becton Dickinson VACUTAINER™ Systems, 
Rutherford, New Jersey). 
 
2. 3. 2  Isolation of Lymphocytes 
Whole blood was immediately transferred from 6 ml vacutainers into a 75cm2 sterile tissue 
culture flask and diluted by approximately 50% with RPMI 1640. The cell suspension was 
separated using a density gradient centrifugation method created by Boyum in 1976, which 
isolates peripheral mononuclear cells from whole blood (Boyum, 1976).  Approximately 8 ml of 
Lymphoprep (Axis-Shield, Oslo, Norway) was added to 8 separate universal containers (Dynalab, 










sterile pipette.  All tubes were then centrifuged at 450 x g for 25 min.  A distinct layer of 
mononuclear cells was extracted from each container, using a sterile, manual 2 ml pipet, and 
condensed into 4 fresh universal containers. The cell suspension was then topped off to fill the 
containers, and 3 additional centrifugation steps were performed to compound all cells present 
from the separation into one pellet. Isolated cells were transferred into another tissue culture flask 
containing 20 ml of RPMI 1640 with 10% FBS, and incubated at 37°C, in 5% CO2, for 90 min in 
order to allow monocytes to adhere to the plastic, while the non-adherent cells (lymphocytes) 
remain in suspension.  The lymphocyte suspension was decanted into a new universal container, 
topped off with RPMI 1640 and centrifuged at 200 x g for 10 min.  A cell count was performed 
on the final cell suspension in an improved Neubauer counting chamber by diluting whole blood 
by adding 10 μl of blood into 90 μl of Trypan Blue stain (Sigma, St. Louis, MO). Cell purity was 
also determined by differential counting of lymphocytes and monocytes using May-
Grunwald/Giemsa stain (Sigma, St. Louis, MO).  In all experiments, the mean lymphocyte purity 
was determined to be 91 ± 5%. 
 
2. 3. 3 Preparation of LAK Cells 
Non-adherent lymphocytes derived from 50 ml of blood were further divided into two aliquots 
containing equal number of cells when experiments were planned to include LAK cells.  The cells 
were centrifuged, the pellets resuspended, and counted to 1 x 106 cells/ml in either RPMI 1640 
with 10% FBS (control cells) or RPMI 1640 with 10% FBS, supplemented with IL-2 (2.5 ng/ml 
final concentration; R&D Systems, Minneapolis, MN) to make LAK cells.  Lymphocytes (both 
aliquots) were incubated at 37ºC upright in 25cm2 tissue culture flask for approximately 72 hours. 
After this time, the cell suspensions were decanted into universal containers, washed by 










and viability assessment performed prior to their inclusion in experiments. 
 
2. 3 .4  Assessment of Cell Numbers and Viability 
Leukocyte, tumor cell, and endothelial cell number and viability were determined by the addition 
of 10 µl of cell suspension to 90 µL of Trypan Blue (Sigma; St. Louis, MO).  The cell 
suspensions were placed in an improved Neubauer hemocytometer chamber.  The number of cells 
occupying the central 20 squares was counted and divided by 10, so as to obtain the concentration 
of cells required (in µl) to obtain a 106 cells/ml final concentration in one milliliter of media. 
 
2. 4  Immunochemistry 
2. 4. 1  Immunostain: von Willebrand’s Factor on HMEC-1   
HMEC-1 cells were adjusted to 5 x 106 cells/ml in one milliliter of RPMI 1640, in sterile 5 ml 
falcon tubes.  The specific monoclonal antibody against von Willebrand’s Factor (Clone 4F9; 
Beckman Coulter, Miami, FL), or isotypic control (IgG1 (mouse); Clone 679.1Mc7; Beckman 
Coulter) was added to the cell suspension and incubated at room temperature for 30 min.  
Equivalent concentrations/volumes of primary antibody and isotypic control were used (5 µg/µl).  
Following initial incubation, tubes were centrifuged at 200 x g for 10 min to wash cells.  The 
supernatant was discarded and subsequently 10 µl (5 µg) of secondary antibody (Oregon Green 
labeled, mouse-anti-goat; Beckman Coulter) was added to 1 milliliter of RPMI 1640, which was 
added to the HMEC-1 pellet and incubated at room temperature for 30 min.  The cells were again 
washed via centrifugation at 200 x g for 10 min.  The supernatant was discarded and the cells 
were resuspended with 1 milliliter of 1% PFA in falcon tubes for 30 min, followed by an 
additional centrifugation step.  The cell pellet was resuspended in 500 µl of RPMI 1640 and 10 µl 










Reagent (Invitrogen, Carlsbad, CA), and sealed with 13mm x13mm pieces of cover glass. 
 
2. 4. 2 Immunostain: CD54 (ICAM-1) on HMEC-1  
HMEC-1 cells were adjusted to 5 x 106 cells in one ml of RPMI 1640, in sterile 5 ml falcon tubes. 
Ten µl of human-anti-mouse CD54 monoclonal antibody labeled with FITC conjugate (Clone 
84H10; Beckman Coulter), or isotypic control (IgG1; Clone 679.1Mc7; Beckman Coulter) were 
added, and incubated for 30 min at room temperature.  Equivalent concentrations/volumes of 
primary antibody and isotypic control were used (5 µg/µl).  Following incubation, tubes were 
centrifuged at 200 x g for 10 min.  The supernatant was discarded and the cells resuspended and 
fixed with 1 milliliter of 1% PFA in falcon tubes for 30 min, followed immediately by an 
additional centrifugation step.   Fixed cells were then resuspended in 500 µl of RPMI 1640.  Ten 
µl of cell solution was transferred to standard microscope slides, mounted with Prolong Antifade 
Reagent, and sealed with 13 mm x13 mm pieces of cover glass.  
 
2. 4. 3 Immunostain: CD25 on Lymphocytes and LAK Cells 
 
Lymphocytes/LAK cells were adjusted to 5 x 106 cells/ml in RPMI 1640, in 5 ml falcon tubes.  
Ten µl of CD25 specific monoclonal antibody (Clone 2A3; BD Biosciences, San Jose, CA) 
 or isotypic control (IgG1; Beckman Coulter) was added to the cell suspension, and allowed to 
incubate for 30 min at room temperature.  Equivalent concentrations/volumes of primary 
antibody and control were used (5 µg/µl).  Following incubation, tubes were centrifuged at 200 x 
g for 10 min.  The supernatant was discarded and subsequently 0.5 µL of secondary antibody 
(Oregon Green labeled, mouse-anti-human; Beckman Coulter) was added to 1 milliliter of RPMI 
1640, which was added to the pellet and incubated at room temperature for 30 min.  The cells 










the cells were resuspended in 500 µL of RPMI 1640.  Cells were then fixed with 1 milliliter of 
1% PFA in falcon tubes for 30 min, followed immediately by an additional centrifugation.  The 
pellet was resuspended in RPMI 1640 and 10 µL of cell solution was then transferred to standard 
microscope slides, mounted with Prolong Antifade Reagent, and sealed with 13mm x13mm 
pieces of cover glass.  
 
2. 5  Preparation of SFn and Its Components, Fluorescent Probes, and Peptides 
2. 5. 1  Preparation of Fibrinogen 
Human, plasma derived fibrinogen (plasminogen-, fibronectin-, and factor XIII free) was 
obtained from American Diagnostica Inc. (Greenwich, Connecticut).  The lyophilized stock 
amount (5 mg) was reconstituted in 2 ml of sterile deionized H2O, and allowed to sit at room 
temperature for approximately 10 min while gently mixing solution to fully dissolve the reagent.  
Aliquots (25, 50, and 100 µl) of stock fibrinogen were stored in cryo-safe tubes and kept at -80ºC 
until time of experiment. 
 
2. 5. 2 Preparation of Gly-Pro-Arg-Pro  
The fibrin polymerization inhibitor Gly-Pro-Arg-Pro-amide (24 mM; GPRP-NH2) was obtained 
from Sigma Chemical Company (St. Louis, MO).  The lyophilized stock amount (5 mg) was 
reconstituted in 2 ml of sterile, deionized H2O, and allowed to sit at room temperature for 
approximately 10 min while gently mixing solution to fully dissolve the reagent.  Aliquots (42 













2. 5. 3 Preparation of Thrombin 
Thrombin (100 U/ml) was obtained from Sigma Chemical Company.  The lyophilized stock 
amount (5 mg) was reconstituted in 2 ml of sterile, deionized H2O, allowed to sit at room 
temperature for approximately 10 min while gently mixing solution to fully dissolve the reagent.  
Aliquots (5 and 10 µl) of stock thrombin were stored in cryo-safe vials and kept at -80º until time 
of experiment. 
 
2. 5. 4  Preparation of Soluble Fibrin 
SFn is made in the required amount for each experiment.  All component reagents were briefly 
thawed to room temperature.  To make one milliliter of sFn solution, 50 μl fibrinogen (0.5 
mg/ml), 84 μl (4 mM) of GPRP-NH2, followed by 1.25 μl of thrombin were added to 865 μl of 
RPMI 1640 in a sterile, 5 ml falcon tube.  This solution was allowed to sit at room temperature 
for 30 min to form sFn. 
 
2. 5. 5  Preparation of Fluorescent Probes 
Prepackaged, lyophilized probes, 1,1’-dioctadecyl-3,3,3’,3’-tetra-methylindocarbocyanine 
perchlorate, or DiI (fluoresces red) and Calcein AM (fluoresces green), were obtained from 
Invitrogen (Eugene, OR).  Each probe was reconstituted in 50 µl of sterile DMSO (Sigma) 
according to manufacturer recommendations (Akeson, 1993; Gant, 1992). 
 
2. 5. 6  Preparation of Stock Peptides 
Lyophilized peptides (50% purity) were obtained from Sigma-Genoysys (The Woodlands, TX). 
Reconstitution was performed according to the manufacturer recommendations for each.  










concentration in sterile PBS. Peptide 3 was first solubilized in a small amount of DMSO (on 
account of its hydrophobicity), followed by subsequent suspension in PBS, and was made up to a 
100 µM stock concentration. All peptides were divided into 50 µl aliquots, and stored at -20°C.  
 
2. 6  Oregon Green Labeling of Effector Cells 
EC, lymphocytes, and LAK cells were labeled with fluorescently labeled sFn and viewed 
microscopically. 
 
2. 6. 1 Preparation of Oregon Green Labeled SFn 
Oregon Green labeled fibrinogen was obtained from Molecular Probes (Oregon Green 488 human 
fibrinogen conjugate). Lyophilized stock fibrinogen (5 mg) was made up in RPMI 1640 to a total 
volume of 5 ml, aliquotted into cryovials (25 µl each), and stored at -20°C. At time of 
experiment, fluorescent sFn monomer (one milliliter) was made by thawing and adding 50 μl of 
Oregon Green labeled fibrinogen, 84 μl of the fibrin polymerization inhibitor GPRP (24 mM), 
followed by 1.25 μl thrombin (100 U/ml) to 865 μl of RPMI 1640 in a 5 ml falcon tube.  This 
solution was incubated at room temperature for 30 min prior to use in assay. 
 
2. 6. 2  Preparation of Effector Cells 
Lymphocytes, LAK cells, and EC were all cultured and isolated as discussed in previous sections, 
counted to 5.0 x 106 cells per ml, and centrifuged at 200 x g for 10 min to obtain pellets.  One ml 
of prepared, fluorescently labeled sFn was added to each cell type, and allowed to incubate for 30 
min in a 37ºC, 5% CO2 incubator.  Ten µL of each cell type was added to a microscope slide, 
covered with Prolong Antifade Reagent, and sealed with a 13 x 13 mm coverslip for microscopy. 










discarded, and 500 µl of RPMI 1640 added to each.  Slides were again prepared as previously 
described. 
 
2. 6. 3  Fluorescence Microscopy 
An Olympus BX61 was used (100× oil immersion objective) to observe samples and Applied 
Spectral Imaging Software (Vista, CA) was used to capture images. Using the same microscope 
settings to observe differences in fluorescence between samples, five representative fields were 
captured of each slide for each pretreatment. Images were processed using Image Pro Plus™, 
Version 5.1, (Media Cybernetics, Silver Spring, MD) and deconvolved using AutoDeblur™ 
deconvolution software (Media Cybernetics). 
 
2. 7  Binding of Lymphocytes and LAK Cells to Endothelial Cells Under Flow Conditions  
2. 7 1  Preparation of Endothelial Cells on 40 mm Coverslips 
Round, 40 mm coverslips were purchased from Bioptechs Inc. (Butler, PA).  Coverslips were 
sterilized using a pure grade ethanol wash. HMEC-1 cells were prepared in media as described 
previously and counted to 1 x 106 cell/ml in DMEM with 10% FBS. One ml of cells, plus 4 
additional ml of DMEM with 10% FBS was added to each sterile coverslip, in small Petri dishes. 
Coverslips were incubated in a 37ºC, 5% CO2 incubator, for 24-48 hours, or until confluent. 
Confluence was checked using an inverted, phase-contrast Zeiss microscope. 
 
2. 7. 2  Preparation of Fluorescently Labeled Lymphocytes 
Lymphocytes and LAK cells were isolated as described in previous sections.  Lymphocytes were 
labeled with 5 µl of DiI for 20 min at room temperature, centrifuged at 200 x g for 10 min to 











2. 7. 3  Pretreatment of Effector Cells  
Fluorescently labeled lymphocytes were suspended in 5 ml falcon tubes, (1 x 106 cells/ml each in 
RPMI 1640 with 10% FBS), and confluent HMEC-1 cells grown on coverslips were removed 
from incubators for experimentation. Cells were pretreated with sFn, peptides, or both as 
described below. 
 
2. 7. 3. 1  Pretreatment of Effector Cells with SFn (and Components) 
RPMI 1640 with 10% FBS and DMEM with 10% FBS were removed from lymphocytes (by 
centrifugation) and EC (by manual pipet), respectively.  One milliliter of sFn solution, Fg, GPRP, 
or Thr was added to lymphocytes in tubes, and/or to EC on coverslips.  All cells were incubated 
at 37ºC, with 5% CO2 for 30 min prior to inclusion in assays. 
 
2. 7. 3. 2  Pretreatment of Effector Cells with Peptides Prior to SFn 
RPMI 1640 with 10% FBS and DMEM with 10% FBS were removed from lymphocytes (by 
centrifugation) and EC (by manual pipet), respectively.  Cells were reconstituted in 1 ml peptide 
solutions; EC with P1 and P3 (4 mM) and lymphocytes with P2 and P4 (4 mM) for 30 min, 
followed by treatment with sFn for another 30 min, and incubated at 37ºC, with 5% CO2.    
 
2. 7. 4  Assembly of FCS2 Closed Perfusion System 
Figure 2-1 above shows a detailed setup of the FCS2 apparatus.  Coverslips with a confluent 
HMEC-1 cells were loaded into the FCS2 stage incubator (Bioptechs Inc.) and mounted on the 
stage of a Leica DMIRB inverted fluorescence microscope equipped with a Hamamatsu Color 










pathway was formed (Dimensions 0.5 mm × 14 mm × 25 mm) by separating the microaqueduct 
slide from the coverslip containing cells with a single silicone gasket with a rectangular bore, 
generating near-laminar flow conditions during perfusion. The stage incubator was initially 
connected to a peristaltic pump on the afferent side using 0.062 inch bore S/P medical grade 
silicone tubing (Fisher Scientific, Suwanee, GA).  The efferent side was connected to waste 
initially. After connection of the electronic temperature control, the coverslips were perfused with 
RPMI 1640 to briefly buffer the cells at 37°C for ten min.  The flow rate was set to 0.5 ml/min, 
which corresponds to a shear rate of 132.9 s-1, which falls between the reported range as earlier 
discussed. The inlet was then connected to the tube containing the appropriately treated 
lymphocyte suspension (3 ml total). The efferent tubing was also transferred back to the same 
tube, and Di-I labeled lymphocytes were recirculated across the EC for 1 h, after which, the 
tubing was set up to the initial configuration and the cells were again washed with RPMI for 10 
more min to remove unbound lymphocytes.  
 
2. 7. 5  Image Capture and Quantitative Analysis 
Individual still images in five randomly chosen fields of view were captured at 10 x 
magnification and stored on the computer. Image Pro Plus 5.1 software was used to quantitate the 
number of lymphocytes (labeled red) that were bound in each of the captured images. Software 
automatically selected for all fluorescent pixels present in each image, which separated the 
fluorescent lymphocytes from the black background.  The counts for each treatment were 













2. 8  Endothelial Transmigration Assay  
2. 8. 1 Preparation of Polycarbonate Inserts 
Corning Polycarbonate Transwell Permeable Supports (8 µm pore size; 6.5 mm insert diameter; 
0.33 cm2 growth area; 10 µm membrane thickness) were prepared in sterile, flat-bottomed 24-
well microtiter plates (Fisher Scientific).  HMEC-1 cells were detached from tissue culture flasks 
as previously described and counted to 1 x 106 cells/ml.  200 µl of this cell suspension 
(containing 2 x105 cells) were added to the top well of the inserts and grown for approximately 48 
hours at 37ºC with 5% CO2 conditions. 
 
After cells were grown to probable confluence (approximately 48 h), a single representative insert  
was labeled with 2 µl of stock fluorescent probe Calcein AM for 20 min at room temperature. 
After incubation, the insert was gently washed with a sterile pipette three times with fresh DMEM 
media to remove excess probe, and fluorescence microscopy was performed, using an inverted 
Leica DMIRBE, with a 10x objective, to determine whether culture had grown to approximately 
90%+ confluence for continuance of assay (using 488nm excitation; 535nm emission). Figure 2-3 
is a representative image of a fluorescently labeled insert.  
 
 










2. 8. 2 Preparation of Tumor Cells in 24-well Plates 
The cell line A375 (1 x 105 cells/well) was grown on the bottom of 24-well tissue culture-treated 
microplates at 37ºC with 5% CO2 conditions for approximately 24 hours, or until confluence. 
 
2. 8. 3 Preparation of Tumor Cell Conditioned Media (TCCM) 
A375 cell cultures were grown to approximately 75-80% confluence, media aspirated, cells rinsed 
with 5 ml of PBS, and incubated in 10 ml of fresh, serum free, RPMI 1640 for approximately 24 
hours at 37°C/5% CO2.  After 24 hours, the media were collected and subjected to centrifugation 
(200 x g, 10 min) to remove debris, concentrated, and transferred to sterile, 15 ml conical tubes 
until time of experiment. 
 
2. 8. 4  Preparation of eACA 
6-Aminohexanoic acid (eACA) is a lysine analog that promotes rapid dissociation of plasmin 
from cells, which inhibits the activation of plasminogen and subsequent fibrinolysis.  
Furthermore, EACA has been used to inhibit fibrin degradation by cells.  Therefore, this reagent 
was used during some experiments along with sFn in order to study its effect on diapedesis over 
an 18 hour incubation period. 
 
Stock concentration of eACA (Sigma) was made up to 400 mM in RPMI 1640.  50 µL of stock 
solution was added to 1ml of sFn total solution, for a working concentration of 20 mM. 
 
2. 8. 5  Preparation of Effector Cells for Transmigration Assays  
Lymphocytes and LAK cells were isolated and labeled, and EC were isolated and seeded on 
inserts as previously described in previous sections. Cells were then pretreated with sFn (and 










2. 8. 6  Pretreatment with Soluble Fibrin and Components 
RPMI 1640 with 10% FBS and DMEM with 10% FBS were removed from lymphocytes and 
LAK cells (by centrifugation at 200 x g) and EC (by manual pipet), respectively. SFn was 
prepared as described earlier, and the 1 milliliter solutions of sFn, Fg, GPRP, or Thr was added to 
lymphocytes in 5 ml falcon tubes, and/or to EC on coverslips.  All cells were incubated at 37ºC, 
with 5% CO2 for 30 min prior to inclusion in assays. 
 
2. 8. 7  Pretreatment with Peptides Prior to Soluble Fibrin 
RPMI 1640 with 10% FBS and DMEM with 10% FBS were removed from lymphocytes and 
LAK cells (by centrifugation at 200 x g) and EC (by manual pipet), respectively.  Cells were then 
reconstituted in one ml of peptide solution (40 µl of each peptide in pair with 920 µl RPMI;4 mM 
concentration each). EC were pretreated with P1 and P3 and lymphocytes with P2 and P4 for 30 
min, followed by treatment with sFn (one milliliter total) for another 30 min, and incubated at 
37ºC, with 5% CO2.
 
2. 8. 8  Transmigration Assay Setup 
Having completed all experimental preparation as described in the previous sections, the assay 
could be assembled as described below.  The 24-well plate (containing the pretreated, confluent 
endothelial monolayers grown on inserts), was removed from incubation, and the excess DMEM 
present in the inserts was gently extracted using a 200 µl pipette and sterile tips.  Inserts were 
gently washed with DMEM using the same method.  Two hundred µl (containing 2.0 x 105) of 
lymphocytes or LAK cells (either untreated, or pretreated in sFn, Fg, GPRP, Thr, or peptides) 
were added to the top of the appropriate pretreated insert. Another 24-well plate was prepared to 










appropriate wells (to match the number of inserts being tested). The inserts were then transferred 
from the original microplate to the new one with the media.  All appropriate controls, including a 
total (maximal lymphocyte migration; 2 x 105 cells), TCCM, and RPMI 1640 media controls 
were also performed.  Assays were incubated overnight at 37ºC, with 5% C02 for approximately 
18 hours. 
 
2. 8. 9  Transmigration Assay Quantitation 
Following 18 hours of incubation, all inserts were gently removed (as to avoid any spilling from 
the insert into the well below) from the 24-well microplate.  The remaining TCCM solution, 
containing the fluorescently labeled lymphocytes/LAK cells that have migrated through the 
endothelial cell monolayer/polycarbonate membrane was measured by a Perkin Elmer Victor 3 
microplate reader equipped for fluorescence. The plate reader was set up to excite with a filter 
specific for excitation at 535 nm, and to emit with a 620 nm filter), to detect the DiI.  The 
excitation lamp was set to 40000, the aperture to normal width, and the capture time lapse to 1 
second. 
 
2. 9  Statistical Analysis Methods 
2. 9. 1  Statistical Analysis of Adherence Assays 
On a given day, I evaluated between 2 and 5 treatment conditions.  For each treatment condition 
performed, I obtained 5 fluorescent counts, taken from 5 randomly selected microscopy fields 
(using Image Pro Plus software to quantitate), and averaged these into a single fluorescence data 
point for that day.  All data were stored on a running spreadsheet (in Microsoft Excel) until 











Using JMP statistical software package (Cary, NC), paired sample t-tests (α=0.05) were 
performed on all relevant treatment combinations.  This test looks at differences between two 
treatments each day the pair of treatments was performed (n = 3-15 days; depending on the pair).  
Two-sided student’s t-tests were performed on all pairs because of uncertain expectations of 
results.  Student’s t-tests provide some useful information about these studies.  However, their 
application is somewhat limited here, because of the low number of degrees of freedom (DF) for 
certain treatment pairs.  In order to overcome this low DF, and provide additional analyses of 
each experimental setup, models were fit using JMP statistical software. 
 
If we are willing to assume error variances are equal for the treatments, then a model can be fit to 
include additional data from other days of experimentation.  Table 2.1 (A) is a representative data 
set that was modeled in JMP to calculate Least Square Means (LSM’s), which estimates new 
averages (LSM’s) assuming each treatment appeared on all dates.  The LSM values for those 
treatments that have been performed all days (+/+ and -/-) will be the same as the standard means 
that were calculated for these same treatment (highlighted in blue; Table 2-1 A,B).  However, the 
means of those treatments that were only performed on some days (+/- and -/+) were adjusted (in 
either an upward or downward direction) to project an LSM value for these treatments 
(highlighted in red; Table 2-1 (B)).  The amount and direction in which these values are adjusted 
is dependent upon the original measurements obtained.  
 
Also using JMP, Tukey’s multiple comparisons tests were performed on all models (on LSM’s) 
to control the overall risk for Type 1 errors, i.e. to control the risk of falsely declaring differences 
between treatments.  This test also identifies significant differences between treatments, but does 










Table 2-1  Computation of Least Square Means for models 
A) Representative data set for fitting Least Square Means 
 (-/-) (+/+) (-/+) (+/-) 
2/8/2007 3519 1131 . . 
2/15/2007 3453 1841 . 2382 
2/18/2007 3497 1428 . 2508 
2/22/2007 3811 2001 3050 . 
2/24/2007 4658 1867 3038 . 
2/27/2007 4094 2043 . . 
2/28/2007 4833 1564 . . 
3/1/2007 5171 1465 . . 
3/2/2007 3586 1433 . . 
3/6/2007 4359 2779 . . 
3/8/2007 3889 1470 . . 
3/10/2007 3002 1272 . . 
3/28/2007 3220 1733 . . 
3/30/2007 3678 2214 2374 2578 
4/2/2007 3192 1938 . . 
Mean 3864.13 1745.27 2820.67 2489.33 
St Dev 639.36 421.76 386.87 99.32 
 
 
B) Representative Least Square Means table 
Level Least Sq Mean Std Error Mean 
Mean (-/-) 3864.13 115.95 3864.13 
Mean (-/+) 2597.91 302.47 2820.67 
Mean (+/-) 2645.79 302.47 2489.33 











2. 9. 2  Statistical Analysis of Lymphocyte Transendothelial Migration Assays 
On a given day, I evaluated between 4 and 8 different treatment conditions.  I obtained one data 
point from each insert prepared, in arbitrary fluorescence units provided by plate reader software 
(depending on set parameters).  When multiple inserts (2) of the same treatment were performed 
in a day (all experiments except optimization assays), individual data points of the same treatment 
were then combined (added) to obtain a mean and standard deviation of each treatment for that 
day.  A total fluorescence measurement and a tissue culture conditioned media (TCCM) control 
were also performed each day.  The mean of the TCCM measurement for each day was 
subtracted from all other treatments (to control out “background” from each measurement). 
 
Using JMP software, matched pair student’s t-tests (one or two-sided) were performed on 
appropriate pairs to determine any significant differences of fluorescence (migration) between 
treatments.   
 
Similar statistical methods were employed as previously described for the binding section above.  
If we are willing to assume error variances are equal for the treatments, then a model can be fit to 
include additional data from other days of treatment.  LSMs were computed assuming all 
treatments appeared on all dates. Also using JMP, Tukey’s multiple comparisons tests were 










CHAPTER 3.  RESULTS 
3. 1  Cellular Immunostaining  
3. 1. 1.  von Willebrand’s Factor on HMEC-1 Cells 
HMEC-1 cells were immunostained for human factor VIII/V or von Willebrand’s Factor (using 
specific monoclonal antibody directed against vWF, and a fluorescently labeled secondary 
antibody) showed significant expression of this cellular molecule (Figure 3-1) compared to the 
purified immunoglobulin matched isotypic control (IgG1).  Furthermore, nonlabeled cells and a 
secondary antibody control were also performed (indicating no autofluorescence, and almost no 
nonspecific binding of secondary antibody, respectively). This signifies that HMEC-1 cells 
contain the storage organelles (Weibel-Palade Bodies), which contain key components of both 
inflammatory and haemostatic processes (vWF secretion). 
 
3. 1. 2  CD54 on HMEC-1 Cells 
HMEC-1 cells immunostained for CD54 showed significant expression of this cellular receptor 
(Figure 3-2) compared to the purified immunoglobulin matched isotypic control (IgG1) indicating 
almost no nonspecific labeling.  This corresponds with reports that this particular cell line (which 
is representative of many vascular EC in vivo) that express this receptor.  
 
3. 1. 3  CD25 on Lymphocytes and LAK Cells 
Lymphocytes and LAK cells immunostained for CD25, both showed increased expression of this 
cellular molecule (Figure 3-4) compared to its purified immunoglobulin matched isotypic control 
(IgG1).  However, as expected, LAK cell signal fluorescence (or fluorescence intensity) was 



































Figure 3-3 CD25 expression on lymphocytes (A) and LAK cells (B) 
 
3. 2  Oregon Green Labeled SFn Pretreatment of LAK and Endothelial Cells 
LAK cells and EC were incubated alone or in the presence of fluorescently labeled sFn.  Figure 3-
4 shows considerable binding of sFn to both LAK cells (A) and EC (B.), whereas no fluorescence 
was observed on cells incubated in the absence of sFn. 
 
3. 3  Lymphocyte and LAK Cell Adherence to Endothelial Cells Under Flow Conditions  
To simulate the fluid shear stresses present in vivo, lymphocytes or LAK cells were perfused 
across coverslips containing adherent HMEC-1 cells that were loaded into the FCS2 stage 
incubator, and mounted on the stage of an inverted fluorescence microscope equipped with a 
camera attached to a computer for data acquisition.  Figure 3-5 is a representative image of 























Figure 3-5  DiI labeled lymphocytes adherent to EC for fluorescence quantitation  
by Image Pro Plus software 
 
3. 3. 1  Lymphocyte Adherence to Endothelial Cells in the Presence of Soluble Fibrin 
SFn pretreatment of one or both cell types (EC/lymphocytes, respectively) significantly affected 
the binding events observed under flow conditions.  Figure 3-6 shows the mean fluorescence 
units measured for each treatment (as determined by IPP software).  Means for each day are listed 
in Table A-1 in the appendix.  Untreated cells of each type (-/-) were used as a control value of 
the maximum number of fluorescence units measured for each experiment.  Each other 
pretreatment measurement was then tested against the untreated control value in order to calculate 
percent inhibition of adherence.  Furthermore, standard deviations for each pretreatment were 
further calculated including only those days that the treatment of interest was performed.  
Pretreatment of both cell types with sFn (+/+), resulted in the fewest number of bound 
lymphocytes to EC (or least fluorescence observed), resulting in a mean ± standard deviation of 
54.1 ± 11.3% inhibition when compared to the control (n=15).  Pretreatment of only EC (+/-) 
resulted in a 29.7 ± 1.4% decrease of binding events (n=3).  Similarly, pretreatment of 








































Figure 3-6. Effect of sFn pretreatment on lymphocyte adherence to endothelial cells (endothelial 
cells and lymphocytes, respectively) under flow conditions.  All measurements are presented as 
percent inhibition compared to untreated cells.  Values were produced by quantitation of 











3. 3. 2  Statistical Analysis: Lymphocyte Binding to Endothelial Cells in the Presence of 
Soluble Fibrin  
Using JMP, matched pair student t-tests (α=0.05; Table A-2) were performed on the original data 
for the four possible pretreatment combinations of sFn (-/-, +/+, -/+, +/-).  When neither cell type 
was pretreated with sFn (-/-), the mean fluorescence measured (binding events) was significantly 
larger than all other treatment means (+/+, +/-, and -/+).  Furthermore, there were no additional 
significant differences found between any of the other treatment combinations. 
 
Also using JMP, an additive model, including terms for date (15 days) and treatment (4 levels), 
was fit using Standard Least Squares.  I obtained an R2 value of 0.91 (Table 3-1; Part A), with 
treatment differences explaining the vast majority of the variation of fluorescence measurements.  
The Root Mean Square Error of 449.1 estimates the assumed standard deviation.  The mean of 
response, and total observations are also listed. 
 
Furthermore, the analysis of variance (ANOVA) (Table 3-1; Part B) provided an F ratio of 
11.3324 (P <.0001) indicating a significant model.  The model accounts for approximately 91% 
of variation (from R2 value), whereas the unexplained variation accounts for the other 9%.  
 
The residuals were also examined, and they were consistent with our assumption of a common 











Table 3-1.  Statistical analysis: lymphocyte adherence to endothelial cells in the presence of 
soluble fibrin. 
 
A) Summary of Fit  
RSquare 0.914551 
Root Mean Square Error 449.061 
Mean of Response 2779.744 
Observations (or Sum Wgts) 36 
 
B) Analysis of Variance 
 
Source DF Sum of Squares Mean Square F Ratio 
Model 17 38849167 2285245 11.3324 
Error 18 3629805 201656 Prob > F 
C. Total 35 42478971  <.0001 
 
 


















D) Effect Tests 
 
Source Nparm DF Sum of Squares F Ratio Prob > F
Date 14 14 4903330 1.7368 0.1345
Treatment 3 3 33794276 55.8613 <.0001
 
 
E) Least Squares Means Table   
 
Level Least Sq Mean Std Error Mean 
Mean (-/-) 3864.0933 115.94706 3864.09 
Mean (-/+) 2597.9093 302.46841 2820.60 
Mean (+/-) 2645.7950 302.46841 2489.27 










The Effect Tests Table (Table 3-1; Part D) indicates that the date (DF=14) of the experiment was 
found to be an insignificant factor (P=0.1345; F Ratio=1.7638).  However, pretreatment (DF=3) 
was found to be a significant factor (P < .0001; F Ratio=55.86). 
 
Table 3-1, Part E is the Least Square Means table that was generated using this model. 
Furthermore, the specific LSM value is included for each, followed by the computed standard 
error and the simple mean computation.  Note that both the LSM and mean are the same for both 
treatments (-/- and +/+) that were performed all days.  However, the LSM value for (-/+) has been 
adjusted in a downward (negative) direction, and the LSM for (+/-) has been adjusted in an 
upward (positive) direction.  This is due to fact that those days that (-/+) and (+/-) were tested, the 
(-/-) and (+/+) pretreatment measurements tended to be higher and lower (respectively) than other 
days. 
 
Using the computed LSM values, Tukey’s multiple comparison method was performed. Table 3-2 
includes the specific details for each sFn pretreatment, including the lower and upper bounds 
(confidence intervals) with 95% certainty (CL Dif).  Those values that are in red correspond to 
significant differences in the model. 
 
Using this method, it was again shown that when neither cell was pretreated (-/-), the average 
fluorescence measured was significantly different than all other pretreatments involving sFn. 
However, when both cell types were treated with sFn (+/+) was not significantly different than 
other intermediate treatments’ fluorescence.  Furthermore, the intermediate treatments’ 











Table 3-2. LSM differences Tukey’s multiple comparison method: Lymphocyte adherence to 
endothelial cells in the presence of soluble fibrin. Those columns in red are significant. 
 
A) LSMeans differences Tukey’s table. α=0.050; Q=2.82629. 
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif 



































































B) Tukey’s summary. Levels not connected by same letter are significantly different. 
Level   Least Sq Mean
Mean (-/-) A   3864.0933
Mean (+/-)   B 2645.7950
Mean (-/+)   B 2597.9093











3. 3. 3  Lymphocyte Adherence to Endothelial Cells in the Presence of Fibrinogen, GPRP, 
and Thrombin 
Untreated cells of each type (-/-) were used as a control value to obtain the maximum 
fluorescence (binding) measured (n = 15).  Figure 3-7 shows the mean fluorescence units 
measured for each treatment (as determined by IPP software).  Pretreatment of both cell types 
with sFn (+/+) resulted in the fewest number of bound lymphocytes to EC, resulting in a 54.1 ± 
11.3% inhibition of fluorescence when compared to the control.  Cells pretreated with fibrinogen 
resulted in a 6.8 ± 10.30% inhibition of binding events (n = 3).  Cells pretreated with GPRP 
resulted in a 5.1 ± 3.3% decrease of binding events (n = 3).  And when both cells were pretreated 
with thrombin, fluorescence was only decreased by 4.0 ± 5.8% (n=3).  Means for each treatment 
combination for each day of experimentation are presented in Table A-1 in the appendix. 
 
3. 3. 4  Statistical Analysis: Lymphocyte Adherence to Endothelial Cells in the Presence of 
Fibrinogen, GPRP, and Thrombin 
Using JMP, matched pair student t-tests (α = 0.05) were performed on the original data for 
appropriate pairs of the five possible pretreatment combinations (-/-, +/+, Fg/Fg, GPRP/GPRP, 
Thr/Thr). Individual tests for all appropriate tests are listed in Table A- 2 in the appendix.  When 
both cell types were pretreated with sFn (+/+), the mean fluorescence measured was significantly 
different than all other treatments performed (-/-, Fg,Fg, Thr/Thr, GPRP/GPRP).  Furthermore, 
there were no additional significant differences found between any of the other treatment 
combinations (Table A-2). 
 
Also using JMP, an additive model, including terms for date (15 days) and treatment (5 levels), 
































































Figure 3-7. Effect of soluble fibrin components (fibrinogen, GPRP, and thrombin individually) 
on lymphocyte adherence to endothelial cells under flow conditions. All measurements are 
presented as percent inhibition compared to untreated cells.  Values were produced by 
quantitation of adherent, fluorescently labeled lymphocytes to endothelial cells using Image Pro 











Table 3-3. Statistical analysis: lymphocyte adherence to endothelial cells in the presence of 
fibrinogen, GPRP, and thrombin. 
 
A) Summary of Fit  
 
RSquare 0.920619 
Root Mean Square Error 440.6393 
Mean of Response 3003.533 
Observations (or Sum Wgts) 39 
 
 
B) Analysis of Variance 
 
Source DF Sum of Squares Mean Square F Ratio
Model 18 45035802 2501989 12.8860
Error 20 3883260 194163 Prob > F
C. Total 38 48919062  <.0001
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D) Effect Tests 
 
Source Nparm DF Sum of Squares F Ratio Prob > F
Date 14 14 6184911 2.2753 0.0455
Label 4 4 35002211 45.0681 <.0001
 
E) Least Squares Means Table 
Level Least Sq Mean Std Error Mean 
Mean(Fg/Fg) 3312.8067 301.01394 3575.67 
Mean(GPRP/GPRP) 3417.7400 301.01394 3680.60 
Mean(-/-) 3864.0933 113.77258 3864.09 
Mean(+/+) 1745.3200 113.77258 1745.32 











treatment differences explaining the majority of the variation of fluorescence.  The Root Mean 
Square Error of 440.6 estimates the assumed common standard deviation.  The mean response 
and total observations (39) are also listed. 
 
Furthermore, the ANOVA (Table 3-3 (B)) provided an F ratio of 12.89 (P <.0001), indicating a 
significant model.  This model accounts for approximately 92% of variation (from R2 value), 
whereas the unexplained variation accounts for the remaining 8%. 
  
The residuals for the model were also examined, and they were consistent with the assumption of 
a common variance.  There are no “extreme outliers” that need additional attention for this model 
(Table 3-3 (C)). 
 
The Effect Tests Table (Table 3-3 (D)) indicates that the date (DF=14) of the experiment was 
found to be a significant factor (P=0.046; F Ratio=2.28).  This could be due to the fact that 
different aliquots of reagents (blood, soluble fibrin, EC, probes, etc.) are used daily, which could 
influence final results. Pretreatment (DF=4) was also found to be a significant factor (P < .0001; 
F Ratio=45.07).   
 
Table 3-3 (E) is the Least Square Means table that was generated using this model. Furthermore, 
the specific LSM value is included for each, followed by the computed standard error and the 
standard mean computation.  Note that both the LSM and mean are again the same for both 
treatments (-/- and +/+) because they were performed all days.  However, the LSM value for all 
other treatments (Fg/Fg, GPRP/GPRP, Thr/Thr) have all been adjusted in a downward (negative) 










measurements tended to be higher than for the other days. 
 
Tukey’s multiple comparison method (α = 0.05) was then performed on the LSM values, for all 
pairs of the five possible pretreatment combinations (-/-, +/+, Fg/Fg, GPRP/GPRP, Thr/Thr). 
Table 3-4 (A) includes the specific details for each sFn component pretreatment, including the 
lower and upper bounds with 95% certainty (CL Dif).  Those columns that are in red correspond 
to those values that are significant in the model.  Furthermore, Table 3-4 (B) is a summary of 
these results.  When pretreating both cell types with sFn (+/+), the average fluorescence 
measurement was significantly different than all other pretreatments.  None of these controls’ 
average fluorescence measurements were found to be significantly different than when neither 
cell type (-/-) was pretreated.  Furthermore, there were no additional significant differences found 
between any of the other treatment combinations. 
 
3. 3. 5  Lymphocyte Adherence to Endothelial Cells in the Presence Peptides and SFn 
SFn pretreatment of one or both cell types significantly affected the binding events observed 
under flow conditions.  Figure 3-8 represents the mean fluorescence measurements for each 
treatment performed.  Untreated cells of each type (-/-) were used as a control value to determine 
maximum fluorescence measured (n=15).  Pretreatment of both cell types with sFn (+/+) resulted 
in the fewest number of bound lymphocytes to EC (or least fluorescence observed), resulting in a 
54.1 ± 11.3 % inhibition when compared to the control (n=3).  EC and lymphocytes that were 
treated with both peptides 1 and 3 (P1/P3), prior to sFn exposure, resulted in only a 26.7 ± 4.1% 
inhibition of fluorescence, restoring some binding (n=3).  However, EC and lymphocytes treated 
with peptides 2 and 4 (P2/P4), prior to sFn exposure, resulted in only a 46.1 ± 12.3% inhibition of 










Table 3-4.  LSMs differences Tukey’s multiple comparison method (soluble fibrin components). 
Those columns in red are significant. 
 
A) LSMeans differences Tukey’s table. α=0.050; Q=2.99238. 
 
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif 






































































































B) Summary of Tukey’s table. Levels not connected by same letter are significantly different. 
 
Level   Least Sq Mean
(-/-) A   3864.0933
Thr/Thr A   3479.8667
GPRP/GPRP A   3417.5333
Fg/Fg A   3312.5333





















































Figure 3-8.  Effect of peptide and sFn pretreatment on lymphocyte adherence to endothelial cells 
under flow conditions. All measurements are presented as percent inhibition compared to 
untreated cells.  Values were produced by quantitation of adherent, fluorescently labeled 











3. 3. 6  Statistical Analysis: Lymphocyte Adherence to Endothelial Cells in the Presence of 
Peptides and Soluble Fibrin  
Using JMP, matched pair student t-tests (α = 0.05) were performed on all possible pairs of the 
original data for the four pretreatment combinations (-/-, +/+, P1/P3, and P2/P4).  Specific t-test 
values are listed in Table A- 2 in the appendix.  When neither cell type was pretreated with sFn   
(-/-), the mean fluorescence was significantly larger than when both cells were pretreated (+/+), 
and larger than when cells were pretreated with peptides P2/P4 prior to sFn.  However, when cells 
were pretreated with P1/P3, prior to sFn, the mean fluorescence was found to be significantly 
different than when neither cell was untreated (-/-).  Pretreatment of both cells (+/+) was also 
significantly different than pretreatment with peptides P1/P3. 
 
Also using JMP, an additive model, including terms for date (15 days) and treatment (4 levels), 
was fit using Standard Least Squares.  An R2 value of 0.92 was obtained (Table 3-5 (A)), with 
treatment differences explaining the majority of the variation within fluorescence.  The Root 
Mean Square Error of 447.2 estimates the assumed common standard deviation.  The mean 
response (fluorescence), and total observations (n=36) are also listed. 
 
Furthermore, the ANOVA (Table 3-5; Part B) provided an F ratio of 12.60 (P <.0001), indicating 
a significant model.  This model accounts for approximately 92% of variation (from R2 value), 
whereas the unexplained variation accounts for the remaining 8%.  
 
The residuals were also examined, and they were consistent with our assumption of a common 











Table 3-5. Statistical analysis: lymphocyte adherence to endothelial cells in the presence of 
peptides and soluble fibrin 
 
A) Summary of Fit 
RSquare 0.922488
Root Mean Square Error 447.1762
Mean of Response 2762.667
Observations (or Sum Wgts) 36
 
 
B) Analysis of Variance 
 
Source DF Sum of Squares Mean Square F Ratio 
Model 17 42837068 2519828 12.6012 
Error 18 3599398 199967 Prob > F 
C. Total 35 46436466 <.0001 
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D) Effect Tests 
 
Source Nparm DF Sum of Squares F Ratio Prob > F
Date 14 14 5434470 1.9412 0.0929
Label 3 3 34650112 57.7598 <.0001
 
 
E) Least Squares Means Table  
 
Level Least Sq Mean Std Error Mean 
(+/+) 1745.2667 115.46040 1745.27 
(-/-) 3864.1333 115.46040 3864.13 
P1/P3 3102.7000 305.47951 3306.67 











The Effect Tests Table (Table 3-5 (D)) indicates that the date (DF=14) of the experiment was not 
found to be a significant factor (P=0.093; F Ratio=1.94).  Pretreatment (DF=3) was found to be a 
significant factor (P < .0001; F Ratio=57.76). 
 
Table 3-5 (E) is the Least Square Means table that was generated using this model. The specific 
LSM value is included for each treatment, followed by the computed standard error and the 
standard mean computation.  Note that both the LSM and mean are again the same for both 
treatments (-/- and +/+) because they were performed all days.  However, the LSM values for the 
other treatments (P1/P3 and P2/P4)) have both been adjusted.  P1/P3 has been adjusted in a 
downward (negative) direction, and P2/P4 in an upward (positive) direction.  This is due to fact 
that those days that these treatments were tested, their fluorescence measurements tended to be 
higher and lower, respectively, than projected for the other days. 
 
Tukey’s multiple comparison method (α = 0.05) was then performed on the LSM values, for all 
pairs of the four possible pretreatment combinations (-/-, +/+, P1/P3, P2/P4). Table 3-6 (A) 
includes the specific details for each pretreatment, including the lower and upper bounds with 
95% certainty (CL Dif).  Those columns that are in red correspond to those values that are found 
to significant in the model. When neither cell type was pretreated (-/-), the average fluorescence 
measurement was found to be significantly higher than when both cell types were pretreated with 
sFn (+/+), and when pretreated with P2/P4 prior to exposure to sFn.  However, when cells were 
left untreated (-/-), the average fluorescence was not significantly different than pretreatment with 
P1/P3 peptide pair.  In addition, pretreatment of both cells (+/+) was significantly different than 
treatment with P1/P3, however it was not significantly different than P2/P4 pretreatment 










Table 3-6. LSM differences Tukey’s multiple comparisons method. Those columns in red are 
significant. 
 
A) LSMeans differences Tukey’s HSD. α=0.050; Q=2.82629. 
 
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif 



































































B) Summary of Tukey’s results. Levels not connected by same letter are significantly different. 
 
Level    Least Sq Mean
(-/-) A     3864.1333
P1/P3 A B   3102.7000
P2/P4   B C 2172.0333













3. 3. 7  LAK Cell Adherence to Endothelial Cells in Presence of Soluble Fibrin and Peptides  
SFn pretreatment of one or both cell types (endothelial/LAK cells, respectively) significantly 
affected LAK cell binding to EC observed under flow conditions.  Figure 3-9 shows the mean 
fluorescence units measured for each treatment (-/-, +/+, P1/P3, P2/P4).  Untreated cells of each 
type (-/-) were used as a control value of maximum number of fluorescence units measured for 
each experiment.  Pretreatment of both cell types with sFn (+/+), resulted in the fewest number of 
bound LAK cells to EC (least fluorescence observed), resulting in a 43.9 ± 4.4% inhibition when 
compared to the control (n=2).  Pretreatment of cells with peptides P1/P3 resulted in a  25.1 ± 6.2 
% decrease of binding events (n=2), and pretreatment of cells with peptides P2/P4 resulted in a 
37.05 ±  4.7% decrease of fluorescence (n=2). Specific measurements for each treatment are 
listed in Table A-3 in the appendix. 
 
3. 3. 8  Statistical Analysis: LAK Cell Adherence to Endothelial Cells Under In the Presence 
of Soluble Fibrin and Peptides 
Using JMP, matched pair student t-tests (α = 0.05) were performed on all pairs for the four 
pretreatment combinations (-/-, +/+, P1/P3, and P2/P4).  All specific t-test results are listed in 
Table A-4 in the appendix.  When neither cell type was pretreated (-/-), the mean fluorescence 
was not significantly greater than when both cells were pretreated (+/+), or when cells were 
treated with P2/P4 or P1/P3 peptide pairs, prior to sFn.  This result can be partially explained by 
the low DF employed for the t-test for this comparison.  However, when both cell types were 
prestreated with sFn (+/+), the mean fluorescence was significantly different than pretreatment 
with P1/P3 and P2/P4 peptide pairs.  Finally, when cells were pretreated with either peptide pair, 

























































Figure 3-9.  Effect of soluble fibrin and peptides on LAK cell adherence to endothelial cells 
under flow conditions.  All measurements are presented as percent inhibition compared to 
untreated cells.  Values were produced by quantitation of adherent, fluorescently labeled 












Also using JMP, an additive model, including terms for date (2 days) and treatment (4 levels), 
was fit using Standard Least Squares.  I obtained an R2 value of 0.99 (Table 3-7 (A)), with 
treatment differences explaining virtually all of the variation in fluorescence.  The Root Mean 
Square Error of 179.7 estimates the assumed common standard deviation.  The mean of response 
and total observations (8) are also listed. 
 
Furthermore, the ANOVA (Table 3-7 (B)) provided an F ratio of 50.60 (P <.0044), indicating a 
significant model. The model accounts for approximately 99% of variation (from R2 value), 
whereas, those unexplained variation accounts for the remaining 1%.   
 
The residuals were also examined, which were consistent with our assumption of common 
variance.  There are no “extreme outliers” that need additional attention for this model. (Table 3-7 
(C)). 
 
The Effect Tests Table (Table 3-7 (D) indicates that the date (DF=1) of the experiment was not 
found to be a significant factor (P=0.68; F Ratio=0.21).  Pretreatment (DF=3) was found to be a 
significant factor (P < .0003; F Ratio=67.39). 
 
Table 3-7 (E) is the Least Square Means table that was generated using this model. Furthermore, 
the specific LSM value is included for each, followed by the computed standard error and the 
standard mean computation.  Note that both the LSM and mean are again the same for all 










Table 3-7. Statistical analysis: LAK cell adherence to endothelial cells in the presence of soluble 
fibrin and blocking peptides. 
 
A) Summary of Fit 
 
RSquare 0.985394
Root Mean Square Error 179.656
Mean of Response 3958.7
Observations (or Sum Wgts) 8
 
B) Analysis of Variance 
 
Source DF Sum of Squares Mean Square F Ratio 
Model 4 6532434.2 1633109 50.5978 
Error 3 96828.9 32276 Prob > F 
C. Total 7 6629263.1 0.0044 
 




















D) Effect Tests 
 
Source Nparm DF Sum of Squares F Ratio Prob > F
Date 1 1 6867.9 0.2128 0.6760
Label 3 3 6525566.3 67.3928 0.0030
 
 
E) Least Squares Means Table 
 
Level Least Sq Mean Std Error Mean 
(-/-) 5392.4000 127.03601 5392.40 
(+/+) 3021.6000 127.03601 3021.60 
P1/P3 4031.2000 127.03601 4031.20 











Tukey’s multiple comparison method (α = 0.05) was then performed on the LSM values, for all 
pairs of the five possible pretreatment combinations (-/-, +/+, P1/P3, P2/P4).  Table 3-8 (A) 
includes the specific details for each pretreatment, including the lower and upper bounds with 
95% certainty (CL Dif).  Those columns that are in red correspond to those values that are 
significant in the model.  Table 3-8 (B) is a summary of these results.  When neither cell type was 
pretreated (-/-) with sFn, the average fluorescence was significantly larger than all other 
treatments’ means.  Furthermore, when both cell types were pretreated with sFn (+/+), the 
average fluorescence was significantly different than when neither cell was treated with sFn (-/-), 
and when pretreated with P1/P3 prior to exposure to sFn.  Furthermore, when cells were 
pretreated with the P1/P3 pair, the average fluorescence was not significantly different than P2/P4 
pretreatment according to this model.  Pretreatment with P2/P4 was significantly different than 
when neither cell was pretreated, but not different than when both cell types were pretreated with 
sFn. 
 
3. 4  Lymphocyte Transendothelial Migration Optimization Assays 
 
This section addresses the results of the transendothelial migration assays that were performed in 
order to investigate the ability of lymphocytes and activated LAK cells to permeate through 
confluent monolayers of EC grown on polycarbonate inserts under many different conditions.  
Each section below reports a separate experiment using different methodology. 
 
3. 4. 1  Effect of Tumor Cells and TCCM on Migration 
Lymphocyte migration through EC was measured in the presence and absence of either A375 
tumor cells grown in 24-well microplates, or tissue culture conditioned media (TCCM) solution.  










Table 3-8. LSM differences Tukey’s multiple comparisons method (peptides and soluble fibrin). 
Those columns in red are significant. 
 




Std Err Dif 
Lower CL Dif 
Upper CL Dif 



































































B) Summary of Tukey’s test. Levels not connected by same letter are significantly different. 
 
 
Level    Least Sq Mean
(-/-) A     5392.4000
P1/P3   B   4031.2000
P2/P4   B C 3389.6000













lymphocytes (2 x 105 per well).  Figure 3-10 shows all treatments that were performed as a 
percentage of the total fluorescence count measured (100%).  When lymphocytes were added to 
those wells with A375 tumor cells grown in the plates, 95.3% fluorescence was observed after 18 
hours of incubation with EC. When cells were incubated in the presence of one of two different 
batches of A375 conditioned TCCM (TCCM 1 and TCCM 2), 83.2% and 85.5% fluorescence 
was measured, respectively.  In the absence of tumor cells or TCCM, cells incubated with RPMI 
media instead, resulted in only 17.4% total fluorescence.  Controls including A375 cells grown in 
wells (39.9%), TCCM 1 (33.31%) and TCCM 2 (37.0%), and RPMI media alone (10.6%) were 
also performed. 
 
Since this setup was not replicated, no statistical analysis was performed.  However it is clear 
from Figure 3-10 that the presence of A375 tumor cells and TCCM derived from A375 tumor 
cells acts as a chemoattactant toward the lymphocytes present in inserts (lymph/A375, 
lymph/TCCM1, or lymph/TCCM2 versus the lymph/RPMI treatment).  Additionally, the 
background readings (A375, TCCM1, and TCCM2) were found to be comparable to one another, 
but more than RPMI media alone.  
 
Furthermore, an 18 hour assay was found to be appropriate, as the fluorescence observed from the 
lymphocytes incubated with A375 cells grown in the microplate was quite similar to the total 
(100%), which was one major goal of the exercise.  Furthermore, both batches of 
lymphocyte/TCCM exhibited a similar measurement to one another, and a comparable value as 
compared to the total and the lymphocyte/A375 measurements.  The other control measurements 
(TCCM1, TCCM2, RPMI, and A375) all produced measurements less than half of all other 











































































3. 4. 2  Effect of Various Concentrations of Fibrin(ogen)/Soluble Fibrin on Lymphocyte 
Transendothelial Migration  
Pretreatment with 4 different concentrations of sFn reagents (fibrinogen concentrations included 
0.25, 0.50, 0.75, 1.0 mg/ml, with corresponding increases in GPRP and thrombin concentrations) 
were performed.  Figure 3-11 shows the corresponding levels of inhibition caused by 
pretreatment with each. Pretreatment with 0.25 mg/ml of Fg (in sFn made with corresponding 
levels of GPRP and thrombin) resulted in a 14.10 ± 6.11% inhibition compared to migration 
observed of untreated cells.  Pretreatment with 0.50 mg/ml (and corresponding levels of GPRP 
and thrombin) resulted in a 23.55 ±0.78% inhibition, 0.75 mg/ml resulted in a 23.26 ±2.09 
inhibition, and 1.0 mg/ml (and corresponding levels of GPRP and thrombin) resulted in 20.73 


























Figure 3-11. Effect of fibrin(ogen)/soluble fibrin (at different concentrations) on lymphocyte 
transendothelial migration(measurement represents % inhibition of pretreatment versus the 










3. 4. 3  Effect of eACA and SFn on Lymphocyte Transendothelial Migration  
Figure 3-12 is a summary of results obtained from all treatments performed compared to when 
neither cell type was pretreated (-/-).  When both cell types were pretreated with sFn prior to 
incubation (+/+), 18.0% inhibition of migration was observed.  When cells were pretreated with 
sFn, and incubated with EACA (to slow fibrinolysis), 18.5% inhibition was observed.  When 
EACA was incubated with the cells alone, only a 0.1% inhibition was observed (n=1).  Clearly, 
pretreatments with sFn, in the presence or absence of EACA, were not significantly different than 
one another. However, both of these pretreatments were different than EACA alone.  No 
























Figure 3-12. Effect of sFn pretreatment (in the presence of eACA) on lymphocyte 
transendothelial migration(measurement represents % inhibition of pretreatment versus the 










3. 4. 4  The Effect of Various Peptide Concentrations on Lymphocyte Transendothelial 
Migration  
Here, cells were pretreated with each pair of peptides, at three different concentrations (2, 4, and 
8 mM), prior to observation of migration.  Figure 3-13 is a summary of these treatments. 
Pretreatment of both cells with sFn resulted in the maximum level of inhibition at 22.28% (n=1).  
Pretreatment with P1/P3 (at 2, 4, and 8 mM) prior to exposure to sFn, resulted in 9.88, 10.82, and 
7.98%, respectively.  Pretreatment with P2/P4 (at 2, 4, and 8 mM) prior to exposure to sFn, 
resulted in 17.5, 16.83, and 20.38%, respectively. Figure A-11 in the appendix lists all specific 













































Figure 3-13.  Effect of peptide concentration on lymphocyte transendothelial migration 












3. 5  Lymphocyte and LAK Cell Transendothelial Migration in the Presence of Soluble 
Fibrin, Peptides, Fibrinogen, GPRP, and Thrombin  
3. 5. 1  Lymphocyte Transendothelial Migration in the Presence of Soluble Fibrin 
SFn pretreatment of one or both cell types significantly (P < 0.05) affected the number of cells 
that migrated through confluent monolayers of EC grown on 8 µm inserts incubated in 24-well 
plates.  Figure 3-14 is a summary of the mean fluorescence units observed for each pretreatment.  
Untreated cells of each type (-/-) were used as a control value of fluorescence measured (n = 6). 
Furthermore, all other pretreatments were compared against this measurement in order to 
calculate a percent inhibition for each treatment.  Pretreatment of both cell types with sFn (+/+, 
EC/lymphocytes respectively; n = 6) resulted in the fewest number of lymphocytes that migrated 
through the EC (or least fluorescence observed), resulting in 29.60 ± 7.67% inhibition when 
compared to the control (n = 6).  Pretreatment of only EC (+/-) resulted in a 21.31 ± 7.83% 
decrease of migration (n = 2), and pretreatment of lymphocytes only (-/+) resulted in a 17.87 ± 
2.30% decrease of migration (n = 2).  Specific data are listed in Table A-5 in the appendix. 
 
3. 5. 2  Statistical Analysis: Lymphocyte Transendothelial Migration in the Presence of 
Soluble Fibrin 
Using JMP, matched pair student t-tests (α = 0.05) were performed for all possible pairs of the 
four pretreatment combinations of sFn (-/-, +/+, -/+, +/-).  When neither cell type was pretreated 
with sFn (-/-), the mean fluorescence (migration) was significantly greater than double 
pretreatment of cells with sFn (n=6). However, when only one cell type was pretreated with sFn 
(+/-) and (-/+), the mean fluorescence was not found to be significantly different than either 
double sFn (+/+) pretreatment or untreated cells (-/-).  Details for the t-tests appear in Table A-6 





























Figure 3-14.  Effect of soluble fibrin on lymphocyte transendothelial migration (measurement 











Also using JMP, an additive model, including terms for date (6 days) and treatment (4 levels), 
was fit using Standard Least Squares (Table 3-9 (A-E)).  I obtained an R2 value of 0.98  
Table 3-9 (A), with treatment differences explaining the vast majority of the variation within 
fluorescence.  The Root Mean Square Error of 12624.0 estimates the assumed common standard 
deviation.  The mean of response and total observations (16) are also listed. 
 
Furthermore, the analysis of variance (ANOVA) (Table 3-9 (B)) provided an F ratio of 49.8 (P 
<.0001), indicating a significant model. The model accounts for approximately 98% of variation 
(from R2 value), whereas the unexplained variation accounts for the other approximate 2% of 
variance.   
 
The residuals were also examined, and were consistent with our assumption of a common 
variance.  There are no “extreme outliers” that need additional attention for this model (Table 3-9 
(C)). 
 
The Effect Tests Table (Table 3-9(D)) indicates that both date (DF=5) of the experiment and 
pretreatment (DF=3) were found to be significant factors (P<0.0001; F Ratio=39.6 and P < .0001; 
F Ratio=50.4, respectively).  Day could again be a significant factor due to the use of different 
reagents from day to day of experiments. 
 
Table 3-9(E) is the Least Square Means table that was generated using this model.  Furthermore, 
the specific LSM value is included for each, followed by the computed standard error and the 












Table 3- 9.  Statistical analysis: Lymphocyte transendothelial migration in the presence of soluble 
fibrin.  
 
A) Summary of Fit 
RSquare 0.982728
Root Mean Square Error 12624.02
Mean of Response 253010.5
Observations (or Sum Wgts) 16
 
 
B) Analysis of Variance 
 
Source DF Sum of Squares Mean Square F Ratio 
Model 8 6.3472e+10 7.9339e+9 49.7845 
Error 7 1115560289 159365756 Prob > F 


























D) Effect Tests 
 
Source Nparm DF Sum of Squares F Ratio Prob > F
Date 5 5 3.154e+10 39.5825 <.0001
Label 3 3 2.408e+10 50.3671 <.0001
 
 
E) Least Squares Means Table 
 
Level Least Sq Mean Std Error Mean 
(-/-) 310501.00 5153.733 310501 
(-/+) 268712.42 10307.465 219635 
(+/-) 258686.92 10307.465 209609 











treatments (-/- and +/+) because they were performed all days.  However, the LSM values for 
both intermediates (+/- and -/+) have been adjusted in an upward (positive) direction.  This is due 
to fact that those days that (-/+) and (+/-) were tested, the mean fluorescence measurement tended 
to be lower (respectively) than other days included. 
 
Using the computed LSM values, Tukey’s multiple comparison method was performed. Table 3-
10(A) includes the specific details for each sFn pretreatment, including the lower and upper 
bounds (or confidence intervals) with 95% certainty (CL Dif).  Those values that are in red 
correspond to significant differences in the model.  Using this method, it was shown that when 
neither cell was pretreated with sFn (-/-), the average fluorescence measurement was significantly 
different than all other pretreatments involving sFn. Furthermore, when both cell types were 
treated with sFn (+/+), the average fluorescence measurement was significantly different from the 
(-/+) pretreatment mean.  The intermediate treatments’ average measurements were not 
significantly different than one another.  Table 3-10(B) is a summary of these results. 
 
3. 5. 3  Lymphocyte Transendothelial Migration in the Presence of Fibrinogen, GPRP, and 
Thrombin 
Figure 3-15 is a summary of inhibitions observed due to pretreatment of lymphocytes and EC 
with those components that are combined to create sFn in vitro: fibrinogen, GPRP, and thrombin.  
EC and lymphocytes that were pretreated with fibrinogen resulted in a 14.61 ± 3.79% decrease of 
migration (fluorescence) through endothelial monolayers (n=2).  EC and lymphocytes treated 
with GPRP resulted in only a 3.99 ± 2.89% decrease of fluorescence (n=2).  And when both cells 
were pretreated with thrombin, the average fluorescence measurement was decreased by 5.93 ± 










Table 3-10.  LSMeans Differences Tukey’s HSD Multiple Comparison Method. Those columns 
in red are significant. 
 
A) α=0.050   Q=3.31024 LSMean[i] By LSMean[j] 
 
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif 



































































B) Summary of Tukey’s test.Levels not connected by same letter are significantly different. 
 
Level    Least Sq Mean
(-/-) A     310501.00
(-/+)   B   268712.42
(+/-)   B C 258686.92





























Figure 3-15. Effect of soluble fibrin, fibrinogen, GPRP, and thrombin pretreatment on 
lymphocyte transendothelial migration(measurement represents % inhibition of pretreatment 










3. 5. 4  Statistical Analysis: Lymphocyte Transendothelial Migration in the Presence of 
Fibrinogen, GPRP, and Thrombin 
Using JMP, matched pair student t-tests (α = 0.05) were performed on all pairs of interest for the 
five possible pretreatment combinations (-/-, +/+, Fg/Fg, GPRP/GPRP, Thr/Thr).  Individual tests 
are listed in Table A- 6 in the appendix.  When both cells were pretreated with sFn (+/+), the 
mean fluorescence was significantly different than when neither cell was pretreated (n=6).  When 
neither cell type was treated with sFn (-/-), the average fluorescence was not significantly 
different than all other treatments. Similarly, there were no additional significant differences 
found between any of the other treatment combinations.  These not-significant differences are not 
surprising, given that we only have 1 DF for error for each test. 
 
Also using JMP, an additive model, including terms for date (6 days) and treatment (5 levels), 
was fit using Standard Least Squares.  I obtained an R2 value of 0.98 (Table 3-11(A)), with 
treatment differences explaining the vast majority of the variation within fluorescence.  The Root 
Mean Square Error of 11,539 estimates the assumed common standard deviation.  The mean of 
response and total observations (18) are also listed. 
 
Furthermore, the ANOVA (Table 3-11(B)) provided an F ratio of 47.8 (P <.0001), indicating a 
significant model. This model accounts for approximately 98% of variation (from R2 value), 
whereas the unexplained variation accounts for the remaining 2%. 
 
The residuals were also examined, and they were consistent with our assumption of a common 











Table 3- 11.  Statistical analysis: lymphocyte transendothelial migration in the presence of   
A) Summary of Fit 
RSquare 0.981749
Root Mean Square Error 11538.61
Mean of Response 265537.4
Observations (or Sum Wgts) 18
 
 
B) Analysis of Variance 
 
Source DF Sum of Squares Mean Square F Ratio 
Model 9 5.7295e+10 6.3661e+9 47.8150 
Error 8 1065115386 133139423 Prob > F 
C. Total 17 5.836e+10 <.0001 
 
 




















D) Effect Tests 
 
Source Nparm DF Sum of Squares F Ratio Prob > F
Date 5 5 3.2319e+10 48.5490 <.0001
Label 4 4 2.5503e+10 47.8877 <.0001
 
 
E) Least Squares Means Table 
 
Level Least Sq Mean Std Error Mean 
(-/-) 310501.00 4710.6161 310501 
(+/+) 221112.33 4710.6161 221112 
Fg/Fg 262728.04 9421.2322 247060 
GPRP/GRRP 292657.79 9421.2322 276989 










The Effect Tests Table (Table 3-11(D)) indicates that the date (DF=5) of the experiment was 
found to be a significant factor (P<0.0001; F Ratio=48.5).  Pretreatment (DF=4) was also found 
to be a significant factor (P < .0001; F Ratio=47.9).  The use of different reagents could 
contribute to the fact that day was found to be significant as discussed earlier.  
 
Table 3-11(E) is the Least Square Means table that was generated using this model. Furthermore, 
the specific LSM value is included for each, followed by the computed standard error and the 
standard mean computation.  Note that both the LSM and mean are again the same for both 
treatments (-/- and +/+) because they were performed all days.  However, the LSM value for all 
other treatments (Fg/Fg, GPRP/GPRP, Thr/Thr) have all been adjusted in a upward (positive) 
direction.  This is due to fact that those days that these treatments were tested, the fluorescence 
measurements tended to be lower than for the other days. 
 
Using the computed LSM values, Tukey’s multiple comparison method was performed. Table 3-
12(A) includes the specific details for each sFn pretreatment, including the lower and upper 
bounds (or confidence intervals) with 95% certainty (CL Dif).  Those values that are in red 
correspond to significant differences in the model. 
 
Table 3-12(B) includes a summary of these results. Using this method, when both cell types were 
pretreated with sFn (+/+), the average fluorescence was significantly different than all other 
treatments.  Furthermore, when neither cell type was pretreated (-/-), the fluorescence was not 
significantly different than pretreatment with GPRP or thrombin.  However, when neither cell 










Table 3-12. LSMeans Differences Tukey’s HSD multiple comparisons method. Those columns 
in red are significant. 
 
A) LSMean[i] By LSMean[j]; α=0.050; Q=3.45476;  
 
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif 









































































































Level    Least Sq Mean
(-/-) A     310501.00
GPRP/GRRP A B   292657.79
Thr/Thr A B   286616.04
Fg/Fg   B   262728.04











3. 5. 5  Lymphocyte Transendothelial Migration in the Presence of Peptides and Soluble 
Fibrin 
Figure 3-15 is a summary of effects on lymphocyte/EC migration (% inhibitions), caused by 
pretreatment of peptides, prior to incubation with sFn.  When cells and sFn were pretreated with 
both peptides 1 and 3, respectively, resulted in only a 7.92 ± 2.2% inhibition of average 
fluorescence (migration). And when cells and fibrin were pretreated with peptides 2 and 4, 
respectively, resulted in a 9.03 ± 0.58% inhibition of fluorescence. Specific data are listed in 
Table A-5 in the appendix. 
 
3. 5. 6  Statistical Analysis: Lymphocyte Transendothelial Migration in the Presence of 
Peptides and SFn 
Using JMP, matched pair student t-tests (α = 0.05) were performed on all pairs of the original 
data for the four possible pretreatment combinations (-/-, +/+, P1/P3, and P2/P4).  When neither 
cell type was pretreated with sFn (-/-), the average fluorescence was not significantly different 
than the average fluorescence from when both cells were pretreated (+/+).  Furthermore, when 
cells were pretreated with either peptide pair, P1/P3 or P2/P4 prior to sFn, the fluorescence 
measurement was not significantly different than (-/-) or (+/+) fluorescence measurements.  These 
not-significant results are not surprising given the low number of DF (1) for this comparison.  
Details of specific t-test are listed in Figure A-6 in the appendix. 
 
Also using JMP, an additive model, including terms for date (2 days) and treatment (4 levels), 
was fit using Standard Least Squares.  I obtained an R2 value of 0.99 (Table 3-13(A)), with 
treatment differences explaining the vast majority of the variation within fluorescence.  The Root 




























Figure 3-16.  Effect of peptides and soluble fibrin on lymphocyte transendothelial migration 











Table 3-13.   Statistical analysis: lymphocyte transendothelial migration in the presence of  
peptide and soluble fibrin.  
 




Root Mean Square Error 9167.846
Mean of Response 285051.8
Observations (or Sum Wgts) 16
 
 
B) Analysis of Variance 
 
Source DF Sum of Squares Mean Square F Ratio 
Model 8 7.5213e+10 9.4016e+9 111.8580 
Error 7 588345795 84049399 Prob > F 
C. Total 15 7.5801e+10 <.0001 
 
 



















D) Effect Tests 
 
Source Nparm DF Sum of Squares F Ratio Prob > F
Date 5 5 3.3449e+10 79.5938 <.0001
Label 3 3 2.4285e+10 96.3127 <.0001
 
E) Least Squares Means Table 
 
Level Least Sq Mean Std Error Mean 
(-/-) 310501.00 3742.7574 310501 
(+/+) 221112.33 3742.7574 221112 
P1/P3 279958.29 7485.5149 344705 











Furthermore, the ANOVA (Table 3-13(B)) provided an F ratio of 111.8 (P <.0001), indicating a 
significant model.  This model accounts for approximately 99% of variation (from R2 value), 
whereas, the unexplained variation accounts for the other 1% of variation.   
 
The residuals were also examined, which were consistend with our assumption of a common 
variance.  There are no “extreme outliers” that need additional attention for this model (Table 3-
13(C)). 
 
The Effect Tests Table (Table 3-13(D)) indicates that the date (DF=5) of the experiment was 
found to be a significant factor (P<0.0001; F Ratio=79.6).  Pretreatment (DF=3) was also found 
to be a significant factor (P < .0001; F Ratio=96.3). The use of different reagents may have 
contributed to the fact that day was a significant factor. 
 
Table 3-13(E) is the Least Square Means table that was generated using this model. Furthermore, 
the specific LSM value is included for each, followed by the computed standard error and the 
standard mean computation.  Note that both the LSM and mean are again the same for both 
treatments (-/- and +/+) because they were performed all days.  However, the LSM values for the 
other treatments (P1/P3 and P2/P4)) have both been adjusted: P1/P3 in a downward (negative) 
direction, and P2/P4 adjusted in an upward direction.  This is due to fact that the days that these 
treatments were tested, their fluorescence measurement tended to be higher and lower, 
respectively, than the other days of the model. 
 
Using the computed LSM values, Tukey’s multiple comparison method was performed. Table 3-










Table 3-14. LSM Differences Tukey’s HSD multiple comparisons method (peptides and sFn) 
 
A)  α=0.05;Q=3.31024; LSMean[i] By LSMean[j] 
 
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif 



































































B) Summary of Tukey’s test. Levels not connected by same letter are significantly different. 
 
 
Level    Least Sq Mean
(-/-) A     310501.00
P1/P3   B   279958.29
P2/P4   B   276123.79















(confidence intervals) with 95% certainty (CL Dif).  Those values that are in red correspond to 
significant differences in the model. 
 
Using this method, it was again shown that when neither cell was pretreated with sFn (-/-), the 
average fluorescence was significantly different than the other pretreatment of double 
pretreatment with sFn (+/+). Furthermore, when cells were pretreated with either P1/P3 or P2/P4, 
the average fluorescence was significantly different than when both cell types were treated with 
sFn and than when neither was pretreated.  Table 3-14(B) is a summary of these results. 
 
3. 5. 7  IL-2 Activated LAK Cell/Lymphocyte Transendothelial Migration in the Presence of 
Soluble Fibrin and Peptides 
Here, lymphocytes and LAK cells (activated with IL-2) were incubated for approximately 72 
hours.  SFn pretreatment of one or both cell types (EC and 3 day incubated lymphocytes) 
significantly affected the number of cells that migrated through confluent monolayers of EC on 8  
µm inserts in 24-well plates.  Untreated cells (-/-) were used as a control value of maximum 
number of events measured (n=3); a separate control was performed for untreated lymphocytes 
and untreated LAK cells.  Figure 3-17 is a summary of means and standard deviations associated 
with each of these combinations.  Pretreatment of lymphocytes and EC with sFn (+/+, 
EC/lymphocytes respectively; n=3) resulted in the least fluorescence observed, resulting in a 
17.24 ± 0.99% inhibition when compared to its control.  Pretreatment of both EC and IL-2 
activated LAK cells with sFn (LAK +/+) resulted in an 12.24 ± 4.9% inhibition of fluorescence 
(migration), when compared to the control including LAK cells (n=3).   EC and LAK cells that 
were pretreated with P1/P3 resulted in 1.85 ± 8.94% mean inhibition of migration (n=2).  And 













































are listed in figure A-7 in the appendix.  
 
3. 5. 8  Statistical Analysis: LAK Cell Transendothelial Migration in the Presence of Soluble 
Fibrin and Peptides 
Using JMP, matched pair student t-tests (α = 0.05) were performed on all pairs of the original 
data for the four possible pretreatment combinations (-/-, +/+, P1/P3, and P2/P4).  When 3 day 
old lymphocytes and EC were pretreated with sFn (lymph +/+), the mean fluorescence was 
significantly different than when neither cell type was pretreated (lymph -/-).  This combination 
was performed to test the level of migration achieved by these older lymphocytes (in the absence 
and presence of sFn).  When both 3 day old, IL-2 incubated LAK cells and EC were pretreated 
with sFn (LAK +/+), the average fluorescence was not significantly different than when neither 
cell type was pretreated (LAK -/-).  Furthermore, when LAK cells and EC were pretreated with 
either P1/P3 or P2/P4 prior to sFn, the mean fluorescence was not significantly different than 
either (LAK -/-) or (LAK +/+).  These not-significant results are not surprising, given that we 
only have 1 DF for error for each test.  Details of t-tests are listed in Table A-8 of the appendix. 
 
Also using JMP, an additive model, including terms for date (2 days) and treatment (4 levels), 
was fit using Standard Least Squares (Figure 3-15).  I obtained an R2 value of 0.94 (Table 3-
15(A)), with treatment differences explaining the vast majority of the variation within 
fluorescence.  The Root Mean Square Error of 13678 estimates the assumed common standard 
deviation.  The mean of response and total observations (16) are also listed. 
 
Furthermore, the ANOVA (Table 3-15(B)) provided an F ratio of 20.36 (P <.0002), indicating a 










Table 3-15. Statistical analysis: LAK cell transendothelial migration in the presence of sFn and 
peptides. 
 
A) Summary of Fit 
 
RSquare 0.946847
Root Mean Square Error 13677.96
Mean of Response 338778.5
Observations (or Sum Wgts) 16
 
B) Analysis of Variance 
 
Source DF Sum of Squares Mean Square F Ratio 
Model 7 2.6661e+10 3.8087e+9 20.3582 
Error 8 1496691733 187086467 Prob > F 
C. Total 15 2.8158e+10 0.0002 
 
 



















250000 300000 350000 400000
Data Predicted
 
D) Effect Tests 
 
Source Nparm DF Sum of Squares F Ratio Prob > F
Date 2 2 2187730589 5.8468 0.0272
Label 5 5 2.5074e+10 26.8044 <.0001
 
 
E) Least Squares Means Table 
 
Level Least Sq Mean Std Error Mean 
LAK (-/-) 384103.50 7896.971 384104 
LAK (+/+) 336453.83 7896.971 336454 
LAK (P1/P3) 375289.00 10066.703 370287 
LAK (P2/P4) 371002.75 10066.703 366001 
Lymph (-/-) 325696.83 7896.971 325697 










variation accounts for the the remaining 6%.  
 
The residuals were examined, which were consistent with our assumption of a common variance. 
There are no “extreme outliers” that need additional attention for this model (Table 3-15(C)). The 
Effect Tests Table (Table 3-15(D)) indicates that the date (DF=2) of the experiment was not 
found to be a significant factor (P<0.0272; F Ratio=5.85).  Pretreatment (DF=3) was found to be 
a significant factor (P < .0001; F Ratio=26.8). 
 
Table 3-15(E) is the Least Square Means table that was generated using this model. Furthermore, 
the specific LSM value is included for each, followed by the computed standard error and the 
standard mean computation.  Note that both the LSM and mean are again the same for both 
lymphocyte and LAK cell sFn treatments (-/- and +/+) because they were performed all days.  
However, the LSM values for the other treatments (P1/P3 and P2/P4)) have both been adjusted: 
P1/P3 in an upward (positive) direction.  This is due to fact that the days that these treatments 
were tested, fluorescence measurements tended to be lower than the other days of the model. 
 
Using the computed LSM values, Tukey’s multiple comparison method was performed. Table 3-
16(A) includes the details for each sFn treatment, including the lower and upper bounds 
(confidence intervals) with 95% certainty (CL Dif).  Those values in red correspond to significant 
differences in the model.  Using this method, it was shown that when neither cell was pretreated 
with sFn (-/-), the average fluorescence was significantly different than all other pretreatments’ 
average measurements.  Furthermore, when cells were pretreated with either P1/P3 or P2/P4, the 
average fluorescence was significantly different than when both cell types were pretreated with 










 Table 3-16. LSM Differences Tukey’s HSD multiple comparisons method (LAK cells). 
 
A) LSMean[i] By LSMean[j]α=0.050   Q=3.65371  
 
Mean[i]-Mean[j] 
Std Err Dif 
Lower CL Dif 
Upper CL Dif 




























































































































































B) Summary of Tukey’s test. Levels not connected by same letter are significantly different. 
 
Level     Least Sq Mean 
LAK (-/-) A       384103.50 
LAK (P1/P3) A B     375289.00 
LAK (P2/P4) A B C   371002.75 
LAK (+/+)   B C   336453.83 
Lymph (-/-)     C   325696.83 












CHAPTER 4.  SUMMARY OF RESULTS AND CONCLUSIONS 
 OG labeled sFn (sFn) binds to IL-2 activated lymphocytes (LAK cells) and EC. 
 SFn pretreatment inhibited lymphocyte (sign. Student’s t-test and Tukey) and LAK cell 
(sign. Tukey) adherence to EC under flow conditions. 
 SFn reagents (fibrinogen, GPRP, and thrombin individually) did not significantly affect 
lymphocyte/LAK cell adherence to EC under flow conditions.  
 P1/P3 pretreatment, prior to sFn exposure, significantly (Student’s t-test and Tukey) 
restored lymphocyte and LAK cell adherence to EC.  
 P2/P4 pretreatment minimally restored lymphocyte and LAK cell adherence and was not 
a significant factor (Tukey). 
 SFn pretreatment inhibited lymphocyte (sign. Student’s t-test and Tukey) and LAK cell 
(sign. Tukey) transendothelial migration across EC (toward TCCM). 
 SFn components (GPRP, and thrombin individually), did not significantly affect 
(Tukey’s) lymphocyte migration.  However, pretreatment with fibrinogen did 
significantly affect lymphocyte migration through EC.   
 Pretreatment with either peptide pair (P1/P3 or P2/P4), prior to sFn exposure, 
significantly (Tukey) restored both lymphocyte and LAK cell diapedesis through EC. 
 Fibrinolysis was determined to be minimal in the process of the transendothelial 
migration assay. 
 Tested peptide concentrations (2, 4, 8 mM) resulted in comparable levels of inhibition (of 
diapedesis).  
 Fibrinogen concentration (0.25, 0.50, 0.75, 1.0 mg/ml, and corresponding concentrations 
of other reagents to make sFn) was found to be insignificant factor above the 










CHAPTER 5.  DISCUSSION 
The results from these studies confirm the first of our hypotheses that sFn inhibits lymphocyte 
and LAK cell adherence to and diapedesis across endothelial monolayers.   
 
The first aim of this study was to determine if sFn, which is elevated in the circulation of many 
cancer patients, affects the ability of peripheral blood lymphocytes to adhere to endothelium in 
vitro.  
 
Initial experiments demonstrated that Oregon Green labeled sFn binds to both LAK cells and EC 
in vitro.  These results correspond with our previously published data that sFn also binds to 
lymphocytes, monocytes, and tumor cells in vitro (Figures A-7 and A-8; Biggerstaff, 2007, 
Biggerstaff, 2006). 
 
Subsequent experimentation, involving lymphocyte/EC binding assays under flow conditions, 
resulted in a significant inhibition of lymphocyte binding to EC.  Maximal inhibition was 
observed when both cells were pretreated with sFn prior to inclusion in assays, however 
significant inhibition was also observed when only one cell type was pretreated.  These results 
correspond well with our previous findings that sFn also inhibits lymphocyte (Figure A-1; 
Biggerstaff 2007) adherence (and cytotoxicity) to tumor cells by the same integrin mediated 
mechanism.  This hypothesis is further supported due to the inability of individual sFn 
components (fibrinogen, GPRP, and thrombin) to significantly effected lymphocyte binding to 
EC, suggesting that the entire sFn molecule intact is required for inhibition to occur. 
 










A375 melanoma cells is the CD8+ cytotoxic T cell (Biggerstaff, 2007).  The predominant 
mechanism by which T lymphocytes adhere to EC is via CD11a/CD18 (which does not bind 
fibrin(ogen)) binding to EC CD54.  Other leukocytes, such as monocytes, NK cells, and 
neutrophils also express an additional CD54 binding beta-2 integrin, CD11b/CD18, which also 
binds fibrin(ogen).  Our observation that lymphocytes actually bound sFn, but do not express 
CD11b/CD18, would suggest that another receptor is responsible for fibrin binding to 
lymphocytes and LAK cells.  Another leukocyte integrin expressed by lymphocytes, αXβ2 does 
not bind to CD54, but does bind to fibrin(ogen) using the same binding motif as for CD11b.  No 
experiments were performed in this study to investigate the role of αXβ2 sFn/lymphocyte binding.  
 
As discussed previously, Ugarova et al. have found particular peptide sequences corresponding to 
the gamma chain on fibrin(ogen) and complementary sequences on CD11b/Cd18 (P2/P4) and 
CD54 (P1/P3).  In the present study, using lymphocytes as effector cells, only two of these 
peptides, P1 and P3, were anticipated to affect adherence significantly.  However, peptides 2 and 
4 were used in this study to control for other CD11b containing leukocyte subsets which may 
have remained after lymphocyte purification.  As expected, lymphocyte adherence was 
significantly restored with the application of appropriate peptides (P1 and P3), but not by peptides 
P2 and P4.  Thus, peptide blockade of either the CD54 binding site for fibrin, and the fibrin 
binding site for CD54, was confirmed to be an important mechanism in lymphocyte adherence to 
EC under these conditions. 
 
Activated lymphocyte, or LAK cell, adherence to EC was similarly inhibited by sFn, confirming 











LAK cell adherence, in the presence of sFn, was restored with pretreatment of P1/P3, but not 
P2/P4. 
 
Extrapolation of these results to the physiological setting would suggest that, in cancer patients 
with elevated levels of sFn, leukocytes (lymphocytes and monocytes), EC, and circulating tumor 
cells would bind sFn, resulting in the inability of lymphocytes and monocytes to adhere to, and 
subsequently kill, tumor cells, resulting in enhanced metastasis. The use of fibrin blocking 
peptides may represent a novel class of therapeutic agents to reduce sFn mediated 
immunosuppression, and decrease metastasis in many cancers, while avoiding the negative 
bleeding problems commonly associated with anticoagulant therapies, since they do not inhibit 
normal blood coagulation. 
 
Since adherence is a necessary step leading up to diapedesis through endothelium, combined with 
the fact that sFn inhibits lymphocyte/LAK cell adherence, it was hypothesized that under 
comparable conditions, cellular diapedesis would similarly be inhibited.  We have previously 
determined the optimal sFn and peptide conditions in previous studies, however since the 
diapedesis was novel, we optimized the conditions of this assay.  The optimal concentration for 
sFn for inhibition was 0.5 mg/ml.  The maximal restoration of diapedesis was seen using a 4 mM 
concentration of P1 and P3, and 8 mM concentration of peptides for P2/P4.   However, all assays 
were subsequently performed at 4 mM to be comparable with previous studies and to 
accommodate the limited amount of peptide available to our laboratory. 
 
Using an 18-hour static transendothelial migration assay, both lymphocyte and LAK cell 










actual level of inhibition was lower than for adherence.  There are two reasons for this: 1) 
Optimal cell number and experimental model parameters were different for binding and 
transendothelial migration assays.  2) Diapedesis was performed for 18 hours, compared with 1 
hour for adherence.  This may have allowed for these cells to overcome effects of fibrin by the 
employment of other molecular mechanisms such as fibrinolysis.  To test this, we performed 
assays in the presence of the plasmin inhibitor, eACA.  However, no effect was observed. 
 
Although lymphocyte diapedesis was not affected by GPRP or thrombin, some inhibition was 
observed when cells were preincubated with fibrinogen, but to a significantly lower degree than 
sFn.  This may have been because some “immobilization” of fibrinogen occurred over the 18 
hour period in a similar to a fashion reported by Ugarova, et al, although this group demonstrated 
enhanced diapedesis when only EC were incubated with immobilized fibrinogen.  Our previous 
results confirm this effect using sFn enhancement of monocyte adherence to tumor cells, but 
preincubation of both cell types with sFn resulted in pronounced inhibition.  This would suggest 
that in the present study immobilization of fibrinogen on both cell types, would explain the 
observed inhibition.  Since this study is concerned with sFn, further study of the mechanism(s) by 
which immobilized fibrinogen mediates leukocyte/EC interactions is outside the scope of this 
project.  
 
SFn mediated inhibition of lymphocyte and LAK cell diapedesis was blocked by inclusion of 
peptides P1/P3, clearly implicating CD54 as an important mediator of diapedesis, which is 
consistent with previous literature.   
 










was also blocked using peptides P2/P4 to a similar degree observed for P1/P3, implicating 
CD11b/CD18 in the mechanism of diapedesis.  The increased incubation time, from 1 hour to 18 
hours, may have allowed for upregulation of CD11b presence on lymphocytes and LAK cells. 
Alternatively, the αxβ2 integrin present on lymphocytes and LAK cells (to a lesser degree than 
CD11a/CD18) binds to sFn using the same sequence as CD11b.  Although we did not study this 
effect further, our results could possibly suggest a role fort his integrin in diapedesis but not in 
initial binding.  Furthermore, CD11b antigen is present on macrophages, granulocytes, natural 
killer cells, and monocytes. However, it has also been reported on activated lymphocytes (LAK 
cells)(Springer, 1979; Sanchez-Madrid, 1993). Therefore, this may somewhat explain how P2 and 
P4 inhibited LAK cells binding to sFn, compared to lymphocytes 
 
These results demonstrated that sFn is immunosuppressive and may be directly involved in the 
etiology of metastasis. Clinically, elevated sFn levels in cancer patients may significantly reduce 
the effectiveness of currently employed immunotherapies targeted to kill cancer cells in vivo.   
 
The fibrin(ogen)-CD11b/CD18 and -CD54 axes can now be viewed as a potentially useful target 
in the development of new therapeutic strategies for the treatment or prevention of inflammatory 
diseases.  In fact, the potential usefulness of fibrinogen as a target in inflammatory disease has 
already been underscored in studies showing that the pharmacological or genetic depletion of 
fibrinogen in mice can diminish the progression of arthritis (Busso, 1998; and unpublished data).  
 
An important implication of the findings in studies using fibrinogen 390–396A (corresponding to the 
active peptide sequence within P4 which inhibits fibrin binding to CD11b) mice is that effective 










devised that would not necessarily compromise hemostatic function. Therefore, in principle, 
inflammatory responses could be controlled at the level of hemostatic factors without increasing 
the risk of bleeding or thrombotic events (Busso, 1998). 
 
Specifically, recent immunotherapy studies (Rosenberg et al.) have shown that many patients’ 
tumors (generally stage 1) regress when activated LAK cells are introduced back into their 
bloodstreams.  This correlates with the many findings suggesting that those patients in the later 
stages of disease, have elevated levels of sFn and its byproducts.  We hypothesize that the reason 
for observing regression in patients in primarily stage 1 of disease is due, at least in part, to 
increased levels of sFn present in advanced stages of cancer.   
 
This project addressed the role of sFn in specific lymphocyte adherence and diapedesis across 
endothelium to tumors.  However, it would not necessarily be expected that tumor cell crossing of 
the endothelial barrier would be inhibited by sFn, since the mechanism of tumor cell 
extravasation is not β2 integrin mediated. However, other adhesive mechanisms involving 
integrins such as αVβ3 (which also binds fibrinogen) may be affected by sFn, but most 
tumor/endothelial interactions involve preliminary lodgment in microcapillaries due to the large 
size of most tumor cells.  Under such conditions, downstream hemostasis, as well as tumor cells 
and platelet release of cytokines such as VEGF, may cause endothelial death and partitioning, 
respectively.  This would allow tumor cells to escape into secondary organs by a nonspecific 
extravasation through gaps in endothelium.  
 
In summary, the results obtained in this project have demonstrated that sFn inhibits both 










light of current immunotherapy protocols, elevated levels of sFn in the blood would be likely to 
interact with reintroduced, activated lymphocytes as well as precoating existing vascular 
endothelium.  This would diminish the ability of therapeutic immune cells to adhere to blood 
vessel walls and home to tumors in order to kill them.  Our data have shown that this inhibition 
can be blocked using specific peptides.  The therapeutic use of such peptides may therefore 
enhance the ability of immunotherapeutic cells to reach their targets, resulting in decreased 
metastasis and possibly enhancing the natural immune response to tumors. 
 
Together with our previous work, the data obtained in this project suggests novel mechanisms for 
the growth, progression, and treatment of certain cancers in the future.  To this end, future work 
will concentrate on further defining the cellular mechanisms by which sFn, and its counterparts, 
influence cancer biology.  These include experimental animal models to test the efficacy of 
potential peptide therapies, as well as studies investigating sFn mediated effects on cell signaling 
and receptor expression, directed towards a better understanding of the role of the immune 
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Figure A-1. Inhibition of lymphocyte adherence to tumor cells by sFn. Calcein AM labeled PBL 
were incubated with A375 cells after pre-treatment of A375 and/or PBL with RPMI or sFn prior 
to assay.  sFn pre-treatment of cell type alone resulted in decreased adherence (+/-, -/+; P<0.05; 
n=3). Maximal inhibition occurred when lymphocytes or LAK cells and tumor cells (+/+) were 












Figure A-2.  Sfn inhibition of lymphocyte cytotoxicity against tumor cells. Calcein AM labeled 
PBL incubated with A375 cells after pre-treatment of A375 with or without sFn and pre-treatment 
of PBL with or without sFn prior to assay. sFn pre-treatment of either cell type alone resulted in 
decreased cytotoxicity (+/-, -/+; P<0.05; n=3).  Maximal inhibition of PBL and LAK cell 
cytotoxic activity occurred when both cell types were treated with sFn (+/+; P<0.05 compared to 
single treatment; n=3). Pre-incubation of lymphocytes and tumor cells with recalcified plasma (+ 
GPRP-NH2) also significantly (P < 0.05 compared to untreated; n=3) inhibited lymphocyte 












Figure A-3. Effect of specific blocking peptides designated P1 (binds to CD54)  and P2 (binds to 
αMβ2) on sFn inhibition of monocyte/tumor cell adherence under flow conditions. (from left to 
right): sFn pre-treatment of monocytes  and A375 cells (n=25) significantly (P < 0.01 compared 
to untreated control; n=30) inhibited monocyte adherence. Pretreatment of cells with P1 and P2 
restored cell adherence to levels not significantly different to that of the untreated control (P<0.05 
to fibrin (n=10); P>0.05 to control). Pre-treatment of tumor cells with P1 and monocytes with sFn 
or tumor cells with sFn and monocytes with P2 inhibited adherence to a similar level to that of 
sFn treatment of both cells (P>0.05 to fibrin; n=5 in each case). Pretreatment of effector and 
tumor cells with fibrinogen (Fg), thrombin or GPRP did not significantly inhibit adherence (P > 













Figure A-4. Effect of specific blocking peptides designated P3 (binds CD54 binding site on sFn) 
and P4 (binds to αMβ2 binding site on sFn) on sFn inhibition of monocyte/tumor cell adherence 
under flow conditions. (from left to right): sFn treatment of monocytes and A375 cells (n=25) 
significantly (P < 0.01 compared to untreated control; n=10) inhibited cell adherence. 
Pretreatment of sFn with P3 and P4 restored cell adherence to levels not significantly different to 
the untreated control (P<0.05 to fibrin; n=5; P>0.05 to control). Pre-treatment of tumor cells 
and/or monocytes with either P3+P4, P3 alone or P4 alone were not inhibitory (P > 0.05; n=5 in 














Figure A-5. Effect of monoclonal anti-αLβ2, -αMβ2 and CD54 on monocyte adherence to tumor 
cells under flow conditions in the presence or absence of sFn. Anti-αLβ2 inhibited monocyte 
adherence to untreated cells (P <0.05; n=3), but was significantly (P<0.01 compared to non-sFn 
treated cells; n=3) less effective in blocking monocyte binding to sFn pre-treated tumor cells. 
Conversely, anti-αMβ2 inhibited monocyte adherence to sFn pre-treated tumor cells to a 
significantly (P<0.01) greater extent than to untreated tumor cells. Anti-CD54 inhibited monocyte 
adherence to untreated tumor cells by over 50%, and by over 80% when tumor cells were pre-
incubated with sFn. Isotypic control IgGs or an irrelevant monoclonal antibody (CD4) did not 











Figure A-6. Oregon Green Labeled Soluble Fibrin on A375 Melanoma Cells and Monocytes. 
Oregon Green labeled fibrinogen (0.5 mg/ml; Molecular Probes, Eugene, OR) was treated with 
thrombin (1.25 U) in the presence of 4 mM GPRP-NH2 to produce fluorescently labeled sFn. 
A375 cells were incubated with labeled sFn for 20 min in a Bioptechs FCS2 enclosed stage 
incubator. The residual sFn was washed away by perfusion and the cells were imaged on an 
Olympus BX61 fluorescence microscope equipped with a long pass 535 nm dichroic filter. 
Considerable binding of sFn was observed. A is a representative image showing tumor cell sFn 
binding. In contrast, little or no binding was observed when cells were pre-incubated with 
peptides P1 + P2 (B), or sFn with P3 + P4 (C). Similarly, sFn bound readily to monocytes (D), 
but was inhibited when cells were pre-incubated with P1 + P2 (E), or sFn was pre-treated with P3 











Figure A-7. Oregon Green labeled sFn binding to lymphocytes and tumor cells. Considerable 
binding of sFn was observed with both cell types.  A) OG labeled sFn on lymphocytes, B) 

















Figure A-8. Effect of perfusion flow rate on monocyte adherence to tumor cells. Monocytes (1 
x106/ml) were perfused across a monolayer of A375 cells attached to a coverslip in a perfusion 
stage incubator for 1 h at 370C, and non-adherent cells were washed off by perfusion to waste for 
10 min. Monocyte adherence was maximal at a flow rate of 0.5 ml/min, and linearly decreased as 













Figure A-9. Effect of sFn on monocyte adherence to tumor cells. Calcein AM labeled PBM 
incubated with A375 cells after pre-treatment of A375 and/or PBM with RPMI or sFn prior to 
assay.  sFn pre-treatment of tumor cells significantly increased adherence to untreated A375 cells 
compared to the untreated control (P < 0.01: n=3). Preincubation of monocytes also marginally 
increased adherence to untreated A375 cells (P<  0.05: n=3) compared to the untreated control, 
but to a significantly lower degree than with sFn treated A375 cells (P < 0.01 compared to 
monocyte sFn). sFn pre-treatment of both effector and target cells resulted in a significant 











Figure A-10. Effect of sFn pre-treatment on monocyte cytotoxicity against tumor cells. Calcein 
AM labeled PBM incubated with A375 cells after pre-treatment of A375 with or without sFn and 
pre-treatment of PBM with or without sFn prior to assay. sFn pre-treatment of monocytes was 
slightly inhibitory (P <0.05 compared to untreated control; n=3). Significantly greater inhibition 
was observed when A375 cells were sFn pre-treated (P <0.01 compared to untreated and to 
monocyte treated cells; n =3). Maximal inhibition of PBM cytotoxic activity occurred when both 
cell types were treated with sFn (P<0.01 compared to untreated, monocyte treated or A375 











Table A- 1. Lymphocyte adherence to endothelial cells under flow conditions (measured in fluorescent pixels). 
 
  (-/-) (+/+) (-/+) (+/-) P1/P3 P2/P4 Fg/Fg GPRP/GPRP Thr/Thr 
2/8/2007 3519 1131 . . . . . . . 
2/15/2007 3453 1841 . 2382 . . . . . 
2/18/2007 3497 1428 . 2508 . . . . . 
2/22/2007 3811 2001 3050 . . . . . . 
2/24/2007 4658 1867 3038 . . . . . . 
2/27/2007 4094 2043 . . . . 3599 4021 4167 
2/28/2007 4833 1564 . . 3681 . . . . 
3/1/2007 5171 1465 . . 3545 . . . . 
3/2/2007 3586 1433 . . 2694 . . . . 
3/6/2007 4359 2779 . . . . 3773 3992 4185 
3/8/2007 3889 1470 . . . 1721 . . . 
3/10/2007 3002 1272 . . . 1491 . . . 
3/28/2007 3220 1733 . . . 2183 . . . 
3/30/2007 3678 2214 2374 2578 . . . . . 
4/2/2007 3192 1938 . . . . 3354 3028 2876 
Mean 3864.13 1745.27 2820.67 2489.33 3306.67 1798.33 3575.33 3680.33 3742.67 



















Section 3.3.2  
(+/+) vs (-/-) 15 -2118.80 180.42 -11.74 < 0.0001
(-/+) vs (-/-) 3 -1228.40 250.82 -4.90 0.039
(+/-) vs (-/-) 3 -1053.30 33.13 -31.79 0.001
(-/+) vs (+/+) 3 -793.07 318.57 2.49 0.131
(+/-) vs (+/+) 3 -661.53 215.08 3.08 0.091
Section 3.3.4  
(Fg/Fg) vs (-/-) 3 -306.33 235.64 -1.30 0.323
(GPRP/GPRP) vs (-/-) 3 -201.33 86.70 -2.32 0.053
(Thr/Thr) vs (-/-) 3 -139.00 113.65 -1.22 0.346
(Fg/Fg) vs (+/+) 3 -1322.00 168.91 7.83 0.016
(GPRP/GPRP) vs 
(+/+) 
3 -1427.00 277.78 5.14 0.036
(Thr/Thr) vs (+/+) 3 -1489.33 344.90 4.32 0.050
Section 3.3.6  
(-/-) vs (P1/P3) 3 -1223.80 214.89 5.69 0.029
(+/+) vs (P1/P3) 3 -1819.10 279.27 -6.51 0.023
(+/+) vs (P2/P4) 3 -306.33 72.23 -4.24 0.051















 (-/-) (+/+) P1/P3 P2/P4 
3/22/2007 5551.8 2941.8 3914 3310 
6/20/2007 5233 3101.4 4148.4 3469.2 
Mean 5392.4 3021.6 4031.2 3389.6 

















Comparison n Mean 
Diff 




Section 3.3.8  
(+/+) vs (-/-) 2 -2370.80 239.20 -9.91 0.064
(P1/P3) vs (-/-) 2 -1361.20 276.60 -4.92 0.128
(P1/P3) vs (+/+) 2 -1009.60 37.40 26.99 0.024
(P2/P4) vs (+/+) 2 -368.00 0.20 1840.00 <0.0001
(P2/P4) vs (-/-) 2 -2002.80 239.00 -8.38 0.076
(P1/P3) vs 
(P2/P4) 















DATE neg/neg sfn/sfn neg/sfn sfn/neg TOTAL 
4/4/07 452516.5 352012.5 396175 374956.5 537489.5 
4/11/07 444845.50 340870.5 404759 405926.5 575453.5 
4/14/07 416655.5 338311   513131.5 
4/18/07 487573 411093   563522.5 
4/20/07 514075.5 441411   585990.5 
4/24/07 532001.5 427637.5   595144.5 
Mean 474611.25 385222.5833 400467 390441.5 561788.6667 
St Dev 44163.61 46682.24 6069.80 21899.10 31132.12 
 
 
DATE Fg/Fg GPRP/GPRP Thr/Thr 
4/4/07    
4/11/07    
4/14/07 369434 411335 413702 
4/18/07 451225 469183.5 454733 
4/20/07    
4/24/07    
Mean 410329.5 440259.25 434217.5 
St Dev 57834.97 40905.07 29013.30 
 
 
DATE P1/P3 P2/P4 TC/CM 
4/4/07   163610 
4/11/07   198054.5 
4/14/07   143557.5 
4/18/07   182982.5 
4/20/07 491896 484068.5 165846 
4/24/07 493970 494128.5 130611 
Mean 492933 489098.5 164110.25 

























Section 3.5.2      
(+/+) vs (-/-) 6 -89389 6134 -14.57 <0.0001 
(-/+) vs (-/-) 2 -48214 8127.5 -5.93 0.106 
(+/-) vs (-/-) 2 -58240 19320 -3.01 0.204 
(-/+) vs (+/+) 2 -54025 9863 5.48 0.115 
(+/-) vs (+/+) 2 -44000 21056 2.09 0.284 
(+/-) vs (-/+) 2 -10026 11193 -0.9 0.535 
Section 3.5.4      
(Fg/Fg) vs. (-/-) 2 -41785 5437 -7.69 0.082 
(GPRP/GPRP) vs 
(-/-) 2 -11855 6535 -1.81 0.321 
(Thr/Thr) vs (-/-) 2 -17897 14943 -1.2 0.443 
(Fg/Fg) vs (+/+) 2 -35628 4505 7.91 0.08 
(GPRP/GPRP) vs 
(+/+) 2 -65557 7467 8.78 0.072 
(Thr/Thr) vs (+/+) 2 -59515 15875 3.75 0.166 
Section 3.5.6      
(P1/P3) vs (-/-) 2 -30106 7926 -3.8 0.164 
(P1/P3) vs (+/+) 2 -58408 7924 7.37 0.086 
(P2/P4) vs (+/+) 2 -54574 11917 4.58 0.137 
(P2/P4) vs (-/-) 2 -33940 3933 -8.63 0.073 
























(P2/P4) TC/CM TOTAL 
5/17/07 502584.5 552568 444907 485738.5     157456 547261 
5/26/07 444973.5 504168 390045.5 478595 520158.5 501627 146055.5 538398 























Section 3.5.7      
Lymph (+/+) vs Lymph (-/-) 3 -55991 853 -65.64 0.0002 
LAK (-/-) vs Lymph (-/-) 3 -58406 4652 12.56 0.0063 
LAK (+/+) vs Lymph (+/+) 3 -66748 13927 4.79 0.0409 
LAK (+/+) vs LAK (-/-) 3 -47650 11997.5 -3.97 0.0579 
LAK (P1/P3) vs LAK (-/-) 2 -8312 24303 -0.34 0.7902 
LAK (P1/P3) vs LAK (+/+) 2 -29748 11816 2.52 0.2407 
LAK (P2/P4) vs LAK (-/-) 2 -12598 10057 -1.25 0.4289 
LAK (P2/P4) vs LAK (+/+) 2 -25462 2430 10.48 0.0606 










Table A-9. Lymphocyte transendothelial migration in the presence of various sFn concentrations 
(measured in fluorescence units). 
  
 
DATE (-/-) 0.25 mg/ml 0.5 mg/ml 0.75 mg/ml 1.0 mg/ml TCCM TOTAL 
6/14/07 511695 450246 434956 439015 429014 179103 610593 
6/22/07 514827 480156 429400 427139 455710 151050 587498 
Mean  513261 465201 432178 433077 442362 165076.5 599045.5 















DATE (-/-)  (+/+)  EACA (-/-) EACA (+/+) TC/CM RPMI TOTAL 











Table A-11. Lymphocyte transendothelial migration in the presence of various peptide 
concentrations (measured in fluorescence units). 
 












(8mM) TCCM TOTAL 
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